(19)
(11)EP 3 575 377 A1

(12)EUROPEAN PATENT APPLICATION

(43)Date of publication:
04.12.2019 Bulletin 2019/49

(21)Application number: 19176174.1

(22)Date of filing:  23.05.2019
(51)International Patent Classification (IPC): 
C09K 11/06(2006.01)
H01L 51/50(2006.01)
C09K 11/00(2006.01)
C07D 401/14(2006.01)
(84)Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
KH MA MD TN

(30)Priority: 31.05.2018 DE 102018113036

(71)Applicant: CYNORA GMBH
76646 Bruchsal (DE)

(72)Inventors:
  • JOLY, Damien
    67930 Beinheim (FR)
  • HOHLMANN, Sarah
    76131 Karlsruhe (DE)

(74)Representative: Hoppe, Georg Johannes 
Darani Anwaltskanzlei Beuckestrasse 20
14163 Berlin
14163 Berlin (DE)

  


(54)ORGANIC MOLECULES FOR OPTOELECTRONIC DEVICES


(57) The invention pertains to an organic compound, in particular for the use in optoelectronic devices. According to the invention, the organic compound has
- Two first identical chemical moieties with a structure of formula I,

and
- Four second chemical moieties, each independently from another with a structure of formula II,

and
- One third chemical moiety RA with a structure of formula Py,

wherein the two first chemical moieties are linked to each other via the chemical moiety RA, wherein each dotted bond (" " or " ") in formula Py indicates the binding site of RA to one of the two identical first chemical moieties.










Description


[0001] The invention relates to organic molecules and their use in organic light-emitting diodes (OLEDs) and in other optoelectronic devices.

Description



[0002] The object of the present invention is to provide molecules which are suitable for use in optoelectronic devices.

[0003] This object is achieved by the invention which provides a new class of organic molecules.

[0004] The organic molecules of the invention are preferably purely organic molecules, i.e. they do not contain any metal ions, which is in contrast to metal complexes known for use in optoelectronic devices. Therefore, according to the present invention, it is preferred that the organic molecules are free of metal atoms or metal ions. The pure organic molecules may, however, include metalloids, in particular, B and Si or exceptionally Sn, Se, and Ge.

[0005] According to the present invention, the organic molecules exhibit emission maxima in the blue, sky-blue or green spectral range. The organic molecules exhibit in particular emission maxima between 420 nm and 520 nm, preferably between 440 nm and 495 nm, more preferably between 450 nm and 470 nm. The photoluminescence quantum yields of the organic molecules according to the invention are, in particular, 20% or more. The molecules according to the invention exhibit in particular thermally activated delayed fluorescence (TADF). The use of the molecules according to the invention in an optoelectronic device, for example an organic light-emitting diode (OLED), leads to higher efficiencies of the device. Corresponding OLEDs have a higher stability than OLEDs with known emitter materials and comparable color.

[0006] The organic light-emitting molecules of the invention comprise or consist of two identical first chemical moieties comprising or consisting of a structure of Formula I,

and
  • four second chemical moieties, each independently from another comprising or consisting of a structure of Formula II,

    and
  • one third chemical moiety RA comprising or consisting of a structure of Formula Py,

    wherein each first chemical moiety is linked to two of the four second chemical moieties via a single bond;

    wherein the two first chemical moieties are linked to each other via the chemical moiety RA wherein each dotted bond ("

    " or "

    ") in Formula Py indicates the binding site of RA to one of the two identical first chemical moieties comprising or consisting of a structure of Formula I;

    wherein one of the first chemical moieties is linked to each of the four second chemical moieties via a single bond.



[0007] T is selected from the group consisting of RA and R1.
V is selected from the group consisting of RA and R1.
W is the binding site of a single bond linking one of the first chemical moieties to one of the four second chemical moieties or is selected from the group consisting of RA and R1.
X is the binding site of a single bond linking one of the first chemical moieties to one of the four second chemical moieties or is selected from the group consisting of RA and R1.
Y is the binding site of a single bond linking one of the first chemical moieties to one of the four second chemical moieties or is selected from the group consisting of RA and R1.
Q is selected from the group consisting of N and C-RPy;
LT is selected from the group consisting of N and C-RI.
LV is selected from the group consisting of N and C-RI.
LW is selected from the group consisting of N and C-RW.

[0008] RW is the binding site of a single bond linking one of the first chemical moieties to one of the four second chemical moieties or is RI.
RX is the binding site of a single bond linking one of the first chemical moieties to one of the four second chemical moieties or is RI.
RY is the binding site of a single bond linking one of the first chemical moieties to one of the four second chemical moieties or is RI.
# represents the binding site of a single bond linking the second chemical moieties to one of the first chemical moieties;
Z is at each occurrence independently from another selected from the group consisting of a direct bond, CR3R4, C=CR3R4, C=O, C=NR3, NR3, O, SiR3R4, S, S(O) and S(O)2;

[0009] R1 is at each occurrence independently from another selected from the group consisting of hydrogen,
deuterium,
C1-C5-alkyl,

wherein one or more hydrogen atoms are optionally substituted by deuterium; C2-C8-alkenyl,

wherein one or more hydrogen atoms are optionally substituted by deuterium; C2-C8-alkynyl,

wherein one or more hydrogen atoms are optionally substituted by deuterium; and C6-C18-aryl,

which is optionally substituted with one or more substituents R6.



[0010] RI is at each occurrence independently from another selected from the group consisting of hydrogen,
deuterium,
C1-C5-alkyl,

wherein one or more hydrogen atoms are optionally substituted by deuterium; C2-C8-alkenyl,

wherein one or more hydrogen atoms are optionally substituted by deuterium; C2-C8-alkynyl,

wherein one or more hydrogen atoms are optionally substituted by deuterium; and C6-C18-aryl,

which is optionally substituted with one or more substituents R6.



[0011] RTz is at each occurrence independently from another selected from the group consisting of hydrogen,
deuterium,
C1-C5-alkyl,

wherein one or more hydrogen atoms are optionally substituted by deuterium; C6-C18-aryl,

which is optionally substituted with one or more substituents R6; and C3-C17-heteroaryl,

which is optionally substituted with one or more substituents R6.



[0012] RPy is at each occurrence independently from another selected from the group consisting of hydrogen,
deuterium,
C1-C5-alkyl,

wherein one or more hydrogen atoms are optionally substituted by deuterium; C6-C18-aryl,

which is optionally substituted with one or more substituents R6; and C3-C17-heteroaryl,

which is optionally substituted with one or more substituents R6.



[0013] Ra, R3 and R4 is at each occurrence independently from another selected from the group consisting of hydrogen, deuterium, N(R5)2, OR5, Si(R5)3, B(OR5)2, OSO2R5, CF3, CN, F, Br, I, C1-C40-alkyl,

which is optionally substituted with one or more substituents R5 and

wherein one or more non-adjacent CH2-groups are optionally substituted by R5C=CR5, C≡C, Si(R5)2, Ge(R5)2, Sn(R5)2, C=O, C=S, C=Se, C=NR5, P(=O)(R5), SO, SO2, NR5, O, S or CONR5;

C1-C40-alkoxy,

which is optionally substituted with one or more substituents R5 and

wherein one or more non-adjacent CH2-groups are optionally substituted by R5C=CR5, C≡C, Si(R5)2, Ge(R5)2, Sn(R5)2, C=O, C=S, C=Se, C=NR5, P(=O)(R5), SO, SO2, NR5, O, S or CONR5;

C1-C40-thioalkoxy,

which is optionally substituted with one or more substituents R5 and

wherein one or more non-adjacent CH2-groups are optionally substituted by R5C=CR5, C≡C, Si(R5)2, Ge(R5)2, Sn(R5)2, C=O, C=S, C=Se, C=NR5, P(=O)(R5), SO, SO2, NR5, O, S or CONR5;

C2-C40-alkenyl,

which is optionally substituted with one or more substituents R5 and

wherein one or more non-adjacent CH2-groups are optionally substituted by R5C=CR5, C≡C, Si(R5)2, Ge(R5)2, Sn(R5)2, C=O, C=S, C=Se, C=NR5, P(=O)(R5), SO, SO2, NR5, O, S or CONR5;

C2-C40-alkynyl,

which is optionally substituted with one or more substituents R5 and

wherein one or more non-adjacent CH2-groups are optionally substituted by R5C=CR5, C≡C, Si(R5)2, Ge(R5)2, Sn(R5)2, C=O, C=S, C=Se, C=NR5, P(=O)(R5), SO, SO2, NR5, O, S or CONR5;

C6-C60-aryl,
which is optionally substituted with one or more substituents R5;
C3-C57-heteroaryl,
which is optionally substituted with one or more substituents R5; and
a mono- or polycyclic, aliphatic, aromatic and/or benzo-fused ring system formed by ring-closure with one or more of the other substituents selected from the group consisting of Ra, R3, R4 and R5;

[0014] R5 is at each occurrence independently from another selected from the group consisting of hydrogen, deuterium, N(R6)2, OR6, Si(R6)3, B(OR6)2, OSO2R6, CF3, CN, F, Br, I,
C1-C40-alkyl,

which is optionally substituted with one or more substituents R6 and

wherein one or more non-adjacent CH2-groups are optionally substituted by R6C=CR6, C≡C, Si(R6)2, Ge(R6)2, Sn(R6)2, C=O, C=S, C=Se, C=NR6, P(=O)(R6), SO, SO2, NR6, O, S or CONR6;

C1-C40-alkoxy,

which is optionally substituted with one or more substituents R6 and

wherein one or more non-adjacent CH2-groups are optionally substituted by R6C=CR6, C≡C, Si(R6)2, Ge(R6)2, Sn(R6)2, C=O, C=S, C=Se, C=NR6, P(=O)(R6), SO, SO2, NR6, O, S or CONR6;

C1-C40-thioalkoxy,

which is optionally substituted with one or more substituents R6 and

wherein one or more non-adjacent CH2-groups are optionally substituted by R6C=CR6, C≡C, Si(R6)2, Ge(R6)2, Sn(R6)2, C=O, C=S, C=Se, C=NR6, P(=O)(R6), SO, SO2, NR6, O, S or CONR6;

C2-C40-alkenyl,

which is optionally substituted with one or more substituents R6 and

wherein one or more non-adjacent CH2-groups are optionally substituted by R6C=CR6, C≡C, Si(R6)2, Ge(R6)2, Sn(R6)2, C=O, C=S, C=Se, C=NR6, P(=O)(R6), SO, SO2, NR6, O, S or CONR6;

C2-C40-alkynyl,

which is optionally substituted with one or more substituents R6 and

wherein one or more non-adjacent CH2-groups are optionally substituted by R6C=CR6, C≡C, Si(R6)2, Ge(R6)2, Sn(R6)2, C=O, C=S, C=Se, C=NR6, P(=O)(R6), SO, SO2, NR6, O, S or CONR6;

C6-C60-aryl,
which is optionally substituted with one or more substituents R6; and
C3-C57-heteroaryl,
which is optionally substituted with one or more substituents R6; and
a mono- or polycyclic, aliphatic, aromatic and/or benzo-fused ring system formed by ring-closure with one or more of the other substituents selected from the group consisting of Ra, R3, R4 and R5;

[0015] R6 is at each occurrence independently from another selected from the group consisting of hydrogen, deuterium, OPh (Ph = phenyl), CF3, CN, F,
C1-C5-alkyl,
wherein optionally one or more hydrogen atoms are independently from each other substituted by deuterium, CN, CF3, or F;
C1-C5-alkoxy,
wherein optionally one or more hydrogen atoms are independently from each other substituted by deuterium, CN, CF3, or F;
C1-C5-thioalkoxy,
wherein optionally one or more hydrogen atoms are independently from each other substituted by deuterium, CN, CF3, or F;
C2-C5-alkenyl,
wherein optionally one or more hydrogen atoms are independently from each other substituted by deuterium, CN, CF3, or F;
C2-C5-alkynyl, wherein optionally one or more hydrogen atoms are independently from each other substituted by deuterium, CN, CF3, or F;
C6-C18-aryl,
which is optionally substituted with one or more C1-C5-alkyl substituents;
C3-C17-heteroaryl,
which is optionally substituted with one or more C1-C5-alkyl substituents; N(C6-C18-aryl)2,
N(C3-C17-heteroaryl)2; and
N(C3-C17-heteroaryl)(C6-C18-aryl).

[0016] Optionally, the substituents from the group consisting of Ra, R3, R4 or R5 independently from each other form a mono- or polycyclic, aliphatic, aromatic and/or benzo-fused ring system with one or more of the other (remaining) substituents selected from the group consisting of Ra, R3, R4 or R5.

[0017] If the substituents Ra, R3 and R4 are at each occurrence independently from another selected to be a mono- or polycyclic, aliphatic, aromatic and/or benzo-fused ring system together with one or more of the other substituents Ra, R3, R4 and/or R5 within the organic molecule, it is preferred for Ra, R3 and R4 to form the mono- or polycyclic, aliphatic, aromatic and/or benzo-fused ring system with a substituent Ra, R3, R4 or R5 that is positioned adjacent to it in the ring.

[0018] Furthermore, it is more preferred in certain embodiments for Ra, R3 and R4 to form the mono- or polycyclic, aliphatic, aromatic and/or benzo-fused ring system including at least one or more rings with a ring size of 5 to 8 atoms.

[0019] Moreover, it is preferred for the mono- or polycyclic, aliphatic, aromatic and/or benzo-fused ring system described above to include at least one or more aromatic rings.

[0020] In certain embodiments, the mono- or polycyclic, aliphatic, aromatic and/or benzo-fused ring system mentioned above and herein may itself comprise at least one substituent R5.

[0021] If the substituent R5 is at each occurrence and independently from another selected to form a mono- or polycyclic, aliphatic, aromatic and/or benzo-fused ring system with one or more of the other substituents Ra, R3, R4 or R5 within the organic molecule; it is preferred for R5 to form the mono- or polycyclic, aliphatic, aromatic and/or benzo-fused ring system with an immediately ring-adjacent substituent selected from the group consisting of Ra, R3, R4 and R5.

[0022] Furthermore, in certain embodiments, R5 forms the mono- or polycyclic, aliphatic, aromatic and/or benzo-fused ring system including at least one or more rings with a ring of a size of 5 to 8 atoms.

[0023] Additionally, in certain embodiments of the organic molecule, the mono- or polycyclic, aliphatic, aromatic and/or benzo-fused ring system includes at least one (one, two, etc.) aromatic rings.

[0024] In further embodiments, the mono- or polycyclic, aliphatic, aromatic and/or benzo-fused ring system itself comprises at least one substituent R5.

[0025] Moreover, at least one Q is N;
exactly one substituent selected from the group consisting of T, V, W, X and Y is RA;
exactly one ring member selected from the group consisting of LT, LV, and LW is N;
exactly one substituent selected from the group consisting of W, Y and X represents the binding site of a single bond linking one of the first chemical moieties to one of the four second chemical moieties; and
exactly one substituent selected from the group consisting of RW, RY and RX represents the binding site of a single bond linking one of the first chemical moieties to one of the four second chemical moieties.

[0026] In one embodiment of the invention, the first two identical chemical moieties comprise or consist of a structure of Formula la:

wherein R1, RA, LT, LV, LW, RX and RY are defined as above,

W# is the binding site of a single bond linking the first chemical moieties to one of the four second chemical moieties or is R1,

Y# is the binding site of a single bond linking the first chemical moiety to one of the four second chemical moieties or is R1;

wherein exactly one substituent selected from the group consisting of W# and Y# is the binding site of a single bond linking the first chemical moiety to one of the four second chemical moieties;

wherein exactly one ring member selected from the group consisting of LT, LV, and LW is N;

wherein exactly one substituent selected from the group consisting of RW, RX and RY is the binding site of a single bond linking the first chemical moiety to one of the four second chemical moieties;

and wherein apart from that the aforementioned definitions apply.



[0027] In one embodiment of the invention, the first two identical chemical moieties comprise or consist of a structure of Formula laa:

wherein R1, R1, LT, LV, W#, Y# and RA are defined as above,

LW# is selected from the group consisting of N and C-R1,

Y# is the binding site of a single bond linking one of the first chemical moieties to one of the four second chemical moieties or is R1,

RD is the binding site of a single bond linking one of the first chemical moieties to one of the four second chemical moieties;

wherein exactly one substituent selected from the group consisting of W# and Y# is the binding site of a single bond linking one of the first chemical moieties to one of the four second chemical moieties;

wherein exactly one substituent selected from the group consisting of LV, LT, and LW# is N; and wherein apart from that the aforementioned definitions apply.



[0028] In one embodiment of the invention, the first two identical chemical moieties comprise or consist of a structure of Formula laaa:

wherein R1, R1, W#, Y# and RA are defined as above,

W# is the binding site of a single bond linking one of the first chemical moieties to one of the four second chemical moieties or is R1,

Y# is the binding site of a single bond linking one of the first chemical moieties to one of the four second chemical moieties or is R1,

LV# is selected from the group consisting of C-RI and N;

LW# is selected from the group consisting of C-RI and N;

RD is the binding site of a single bond linking one of the first chemical moieties to one of the four second chemical moieties;

wherein exactly one substituent selected from the group consisting of W# and Y# is the binding site of a single bond linking one of the first chemical moieties to one of the four second chemical moieties;

wherein exactly one substituent selected from the group consisting of LV# and LW# is N;

and wherein apart from that the aforementioned definitions apply.



[0029] In an embodiment of the invention, RA is selected from the group consisting of:



[0030] In a further embodiment of the invention, RA is selected from the group consisting of:



[0031] In a further embodiment of the invention, RA is selected from the group consisting of:



[0032] In one embodiment of the invention, RA is



[0033] In one embodiment of the invention, RA is



[0034] In one embodiment of the invention, RA is



[0035] In one embodiment, R1, R2, and RI is at each occurrence independently from another selected from the group consisting of hydrogen (H), methyl, mesityl, tolyl and phenyl. The term "tolyl" refers to 2-tolyl, 3-tolyl, and 4-tolyl.

[0036] In one embodiment, R1 and RI is at each occurrence independently from another selected from the group consisting of hydrogen (H), methyl, and phenyl.

[0037] In one embodiment, R1 and RI is at each occurrence hydrogen (H).

[0038] In a further embodiment of the invention, RTz is selected from the group consisting of H, methyl, phenyl, which is optionally substituted with one or more substituents R6; 1,3,5-triazinyl, which is optionally substituted with one or more substituents R6; pyridinyl, which is optionally substituted with one or more substituents R6; and pyrimidinyl, which is optionally substituted with one or more substituents R6.

[0039] In a further embodiment of the invention, RTz is selected from the group consisting of H, methyl, phenyl, which is optionally substituted with one or more substituents R6.

[0040] In a further embodiment of the invention, RTz is phenyl, which is optionally substituted with one or more substituents R6.

[0041] In a further embodiment of the invention, RTz is selected from the group consisting of: H, methyl, and phenyl.

[0042] In a further embodiment of the invention, RTz is phenyl at each occurrence.

[0043] In a further embodiment of the invention, RPy is independently from each other selected from the group consisting of: H, methyl,

phenyl, which is optionally substituted with one or more substituents R6;

1,3,5-triazinyl, which is optionally substituted with one or more substituents R6;

pyridinyl, which is optionally substituted with one or more substituents R6; and

pyrimidinyl, which is optionally substituted with one or more substituents R6.



[0044] In a further embodiment of the invention, RPy is selected from the group consisting of: H, methyl, and phenyl.

[0045] In a further embodiment of the invention, RPy is hydrogen at each occurrence.

[0046] In a further embodiment of the invention, RTz and RPy is independently from each other selected from the group consisting of: H, methyl, and phenyl.

[0047] In a further embodiment of the invention, RTz and RPy is phenyl at each occurrence.

[0048] In a further preferred embodiment of the invention, the four second chemical moieties are identical.

[0049] In a further embodiment of the invention, the four second chemical moieties each at each occurrence independently from another comprise or consist of a structure of Formula Ila:

wherein # and Ra are defined as above.

[0050] In a further embodiment of the invention, Ra is at each occurrence independently from another selected from the group consisting of: H,
Me,
iPr,
tBu,
CN,
CF3,
Ph, which is optionally substituted with one or more substituents independently from each other selected from the group consisting of Me, iPr, tBu, CN, CF3, and Ph,
pyridinyl, which is optionally substituted with one or more substituents independently from each other selected from the group consisting of Me, iPr, tBu, CN, CF3, and Ph,
pyrimidinyl, which is optionally substituted with one or more substituents independently from each other selected from the group consisting of Me, iPr, tBu, CN, CF3, and Ph,
carbazolyl, which is optionally substituted with one or more substituents independently from each other selected from the group consisting of Me, iPr, tBu, CN, CF3, and Ph,
triazinyl, which is optionally substituted with one or more substituents independently from each other selected from the group consisting of Me, iPr, tBu, CN, CF3, and Ph,
and N(Ph)2.

[0051] In a further embodiment of the invention, Ra is at each occurrence independently from another selected from the group consisting of H,
Me,
iPr,
tBu,
CN,
CF3,
Ph, which is optionally substituted with one or more substituents independently from each other selected from the group consisting of Me, iPr, tBu, CN, CF3, and Ph,
pyridinyl, which is optionally substituted with one or more substituents independently from each other selected from the group consisting of Me, iPr, tBu, CN, CF3, and Ph,
pyrimidinyl, which is optionally substituted with one or more substituents independently from each other selected from the group consisting of Me, iPr, tBu, CN, CF3, and Ph, and
triazinyl, which is optionally substituted with one or more substituents independently from each other selected from the group consisting of Me, iPr, tBu, CN, CF3, and Ph.

[0052] In a further embodiment of the invention, Ra is at each occurrence independently from another selected from the group consisting of: H,
Me,
tBu,
Ph, which is optionally substituted with one or more substituents independently from each other selected from the group consisting of Me, iPr, tBu, CN, CF3, and Ph,
triazinyl, which is optionally substituted with one or more substituents independently from each other selected from the group consisting of Me, iPr, tBu, CN, CF3, and Ph.

[0053] In a further embodiment of the invention, Ra is H at each occurrence.

[0054] In a further embodiment of the invention, the four second chemical moieties each at each occurrence independently from another comprise or consist of a structure selected from the group consisting of: Formula IIb, Formula IIb-2, Formula IIb-3, and Formula IIb-4:

wherein

Rb is at each occurrence independently from another selected from the group consisting of: deuterium,

N(R5)2,

OR5,

Si(R5)3,

B(OR5)2,

OSO2R5,

CF3,

CN,

F,

Br,

I,

C1-C40-alkyl,

which is optionally substituted with one or more substituents R5 and

wherein one or more non-adjacent CH2-groups are optionally substituted by R5C=CR5, C≡C, Si(R5)2, Ge(R5)2, Sn(R5)2, C=O, C=S, C=Se, C=NR5, P(=O)(R5), SO, SO2, NR5, O, S or CONR5;

C1-C40-alkoxy,

which is optionally substituted with one or more substituents R5 and

wherein one or more non-adjacent CH2-groups are optionally substituted by R5C=CR5, C≡C, Si(R5)2, Ge(R5)2, Sn(R5)2, C=O, C=S, C=Se, C=NR5, P(=O)(R5), SO, SO2, NR5, O, S or CONR5;

C1-C40-thioalkoxy,

which is optionally substituted with one or more substituents R5 and

wherein one or more non-adjacent CH2-groups are optionally substituted by R5C=CR5, C≡C, Si(R5)2, Ge(R5)2, Sn(R5)2, C=O, C=S, C=Se, C=NR5, P(=O)(R5), SO, SO2, NR5, O, S or CONR5;

C2-C40-alkenyl,

which is optionally substituted with one or more substituents R5 and

wherein one or more non-adjacent CH2-groups are optionally substituted by R5C=CR5, C≡C, Si(R5)2, Ge(R5)2, Sn(R5)2, C=O, C=S, C=Se, C=NR5, P(=O)(R5), SO, SO2, NR5, O, S or CONR5;

C2-C40-alkynyl,

which is optionally substituted with one or more substituents R5 and

wherein one or more non-adjacent CH2-groups are optionally substituted by R5C=CR5, C≡C, Si(R5)2, Ge(R5)2, Sn(R5)2, C=O, C=S, C=Se, C=NR5, P(=O)(R5), SO, SO2, NR5, O, S or CONR5;

C6-C60-aryl,
which is optionally substituted with one or more substituents R5; and
C3-C57-heteroaryl,
which is optionally substituted with one or more substituents R5;
for the other variables, the aforementioned definitions apply.



[0055] In one embodiment of the invention, the four second chemical moieties at each occurrence independently from another comprise or consist of a structure selected from the group consisting of: Formula IIc Formula IIc-2, Formula IIc-3 and Formula IIc-4:

wherein the aforementioned definitions apply.

[0056] In a further embodiment of the invention, Rb is at each occurrence independently from another selected from the group consisting of:

Me,

iPr,

tBu,

CN,

CF3,

Ph, which is optionally substituted with one or more substituents independently from each other selected from the group consisting of Me, iPr, tBu, CN, CF3, and Ph,

pyridinyl, which is optionally substituted with one or more substituents independently from each other selected from the group consisting of Me, iPr, tBu, CN, CF3, and Ph,

pyrimidyl, which is optionally substituted with one or more substituents independently from each other selected from the group consisting of Me, iPr, tBu, CN, CF3, and Ph,

carbazolyl, which is optionally substituted with one or more substituents independently from each other selected from the group consisting of Me, iPr, tBu, CN, CF3, and Ph,

triazinyl, which is optionally substituted with one or more substituents independently from each other selected from the group consisting of Me, iPr, tBu, CN, CF3, and Ph,

and N(Ph)2.



[0057] In a further embodiment of the invention, Rb is at each occurrence independently from another selected from the group consisting of:

Me,

iPr,

tBu,

CN,

CF3,

Ph, which is optionally substituted with one or more substituents independently from each other selected from the group consisting of Me, iPr, tBu, CN, CF3, and Ph,

pyridinyl, which is optionally substituted with one or more substituents independently from each other selected from the group consisting of Me, iPr, tBu, CN, CF3, and Ph,

pyrimidinyl, which is optionally substituted with one or more substituents independently from each other selected from the group consisting of Me, iPr, tBu, CN, CF3, and Ph, and

triazinyl, which is optionally substituted with one or more substituents independently from each other selected from the group consisting of Me, iPr, tBu, CN, CF3, and Ph.



[0058] In a further embodiment of the invention, Rb is at each occurrence independently from another selected from the group consisting of:

Me,

tBu,

Ph, which is optionally substituted with one or more substituents independently from each other selected from the group consisting of Me, iPr, tBu, CN, CF3, and Ph,

triazinyl, which is optionally substituted with one or more substituents independently from each other selected from the group consisting of Me, iPr, tBu, CN, CF3, and Ph.



[0059] In the following, exemplary embodiments of the second chemical moiety are shown:



















wherein for #, Z, Ra, R3, R4 and R5 the aforementioned definitions apply.

[0060] In one embodiment, Ra and R5 is at each occurrence independently from another selected from the group consisting of: hydrogen (H), deuterium (D), methyl (Me), i-propyl (CH(CH3)2) (iPr), t-butyl (tBu), phenyl (Ph), CN, CF3, and diphenylamine (NPh2).

[0061] In one embodiment of the invention, the organic molecules comprise or consist of a structure of Formula III-Py, Formula III-Pm, or Formula III-Tz:





wherein for the substituents any one of the aforementioned definition applies.

[0062] In a further embodiment of the invention, the organic molecules comprise or consist of a structure selected from the group of Formula III-Py-1 and Formula III-Py-2:



wherein for the substituents any one of the aforementioned definition applies.

[0063] In a further embodiment of the invention, the organic molecules comprise or consist of a structure selected from the group of Formula III-Pm-1 and Formula III-Pm-2:



wherein for the substituents any one of the aforementioned definition applies.

[0064] In a further embodiment of the invention, the organic molecules comprise or consist of a structure selected from the group of Formula III-Tz-1 and Formula III-Tz-2:



wherein for the substituents any one of the aforementioned definition applies.

[0065] In a further embodiment of the invention, the organic molecules comprise or consist of a structure selected from the group of Formula IIIa-Py-1 and Formula IIIa-Py-2:



wherein

Rc is at each occurrence independently from another selected from the group consisting of Me,

iPr,

tBu,

Ph, which is optionally substituted with one or more substituents independently from each other selected from the group consisting of Me, iPr, tBu, CN, CF3, and Ph,

pyridinyl, which is optionally substituted with one or more substituents independently from each other selected from the group consisting of Me, iPr, tBu, CN, CF3, and Ph,

pyrimidinyl, which is optionally substituted with one or more substituents independently from each other selected from the group consisting of Me, iPr, tBu, CN, CF3, and Ph,

carbazolyl, which is optionally substituted with one or more substituents independently from each other selected from the group consisting of Me, iPr, tBu, CN, CF3, and Ph,

triazinyl, which is optionally substituted with one or more substituents independently from each other selected from the group consisting of Me, iPr, tBu, CN, CF3, and Ph,

and N(Ph)2.



[0066] In a further embodiment of the invention, the organic molecules comprise or consist of a structure selected from the group of Formula IIIa-Pm-1 and Formula IIIa-Pm-2:



wherein for the substituents any one of the aforementioned definition applies.

[0067] In a further embodiment of the invention, the organic molecules comprise or consist of a structure selected from the group of Formula IIIa-Tz-1 and Formula IIIa-Tz-2:



wherein for the substituents any one of the aforementioned definition applies.

[0068] In a further embodiment of the invention, the organic molecules comprise or consist of a structure selected from the group of Formula IIIb-Py-1 and Formula IIIb-Py-2:



wherein for the substituents any one of the aforementioned definition applies.

[0069] In a further embodiment of the invention, the organic molecules comprise or consist of a structure selected from the group of Formula IIIb-Pm-1 and Formula IIIb-Pm-2:



wherein for the substituents any one of the aforementioned definition applies.

[0070] In a further embodiment of the invention, the organic molecules comprise or consist of a structure selected from the group of Formula IIIb-Tz-1 and Formula IIIb-Tz-2:



wherein for the substituents any one of the aforementioned definition applies.

[0071] In one embodiment of the invention, the organic molecules comprise or consist of a structure of Formula IV-Py, Formula IV-Pm, or Formula IV-Tz:





wherein for the substituents any one of the aforementioned definition applies.

[0072] In a further embodiment of the invention, the organic molecules comprise or consist of a structure selected from the group of Formula IV-Py-1 and Formula IV-Py-2:



wherein for the substituents any one of the aforementioned definition applies.

[0073] In a further embodiment of the invention, the organic molecules comprise or consist of a structure selected from the group of Formula IV-Pm-1 and Formula IV-Pm-2:



wherein for the substituents any one of the aforementioned definition applies.

[0074] In a further embodiment of the invention, the organic molecules comprise or consist of a structure selected from the group of Formula IV-Tz-1 and Formula IV-Tz-2:



wherein for the substituents any one of the aforementioned definition applies.

[0075] In a further embodiment of the invention, the organic molecules comprise or consist of a structure selected from the group of Formula IVa-Py-1 and Formula IVa-Py-2:



wherein for the substituents any one of the aforementioned definition applies.

[0076] In a further embodiment of the invention, the organic molecules comprise or consist of a structure selected from the group of Formula IVa-Pm-1 and Formula IVa-Pm-2:



wherein for the substituents any one of the aforementioned definition applies.

[0077] In a further embodiment of the invention, the organic molecules comprise or consist of a structure selected from the group of Formula IVa-Tz-1 and Formula IVa-Tz-2:



wherein for the substituents any one of the aforementioned definition applies.

[0078] In a further embodiment of the invention, the organic molecules comprise or consist of a structure selected from the group of Formula IVb-Py-1 and Formula IVb-Py-2:



wherein for the substituents any one of the aforementioned definition applies.

[0079] In a further embodiment of the invention, the organic molecules comprise or consist of a structure selected from the group of Formula IVb-Pm-1 and Formula IVb-Pm-2:



wherein for the substituents any one of the aforementioned definition applies.

[0080] In a further embodiment of the invention, the organic molecules comprise or consist of a structure selected from the group of Formula IVb-Tz-1 and Formula IVb-Tz-2:



wherein for the substituents any one of the aforementioned definition applies.

[0081] In one embodiment of the invention, the organic molecules comprise or consist of a structure of Formula V-Py, Formula V-Pm, or Formula V-Tz:





wherein for the substituents any one of the aforementioned definition applies.

[0082] In one embodiment of the invention, the organic molecules comprise or consist of a structure of Formula VI-Py, Formula VI-Pm, or Formula VI-Tz:





wherein for the substituents any one of the aforementioned definition applies.

[0083] In one embodiment of the invention, the organic molecules comprise or consist of a structure of Formula VII-Py, Formula VII-Pm, or Formula VII-Tz:





wherein

exactly one ring member selected from the group consisting of LT and LV is N at each occurrence, and

for the remaining variables any of the aforementioned variables apply.



[0084] In one embodiment of the invention Rc is at each occurrence independently from another selected from the group consisting of:

Me,

iPr,

tBu,

Ph, which is optionally substituted with one or more substituents independently from each other selected from the group consisting of Me, iPr, tBu, CN, CF3 and Ph; and

triazinyl, which is optionally substituted with one or more substituents independently from each other selected from the group consisting of Me, iPr, tBu, CN, CF3 and Ph.



[0085] As used throughout the present application, the terms "aryl" and "aromatic" may be understood in the broadest sense as any mono-, bi- or polycyclic aromatic moieties. Accordingly, an aryl group contains 6 to 60 aromatic ring atoms, and a heteroaryl group contains 5 to 60 aromatic ring atoms, of which at least one is a heteroatom. Notwithstanding, throughout the application the number of aromatic ring atoms may be given as subscripted number in the definition of certain substituents. In particular, the heteroaromatic ring includes one to three heteroatoms. Again, the terms "heteroaryl" and "heteroaromatic" may be understood in the broadest sense as any mono-, bi- or polycyclic hetero-aromatic moieties that include at least one heteroatom. The heteroatoms may at each occurrence be the same or different and be individually selected from the group consisting of N, O and S. Accordingly, the term "arylene" refers to a divalent substituent that bears two binding sites to other molecular structures and thereby serving as a linker structure. In case, a group in the exemplary embodiments is defined differently from the definitions given here, for example, the number of aromatic ring atoms or number of heteroatoms differs from the given definition, the definition in the exemplary embodiments is to be applied. According to the invention, a condensed (annulated) aromatic or heteroaromatic polycycle is built of two or more single aromatic or heteroaromatic cycles, which formed the polycycle via a condensation reaction.

[0086] In particular, as used throughout the present application the term aryl group or heteroaryl group comprises groups which can be bound via any position of the aromatic or heteroaromatic group, derived from benzene, naphthaline, anthracene, phenanthrene, pyrene, dihydropyrene, chrysene, perylene, fluoranthene, benzanthracene, benzphenanthrene, tetracene, pentacene, benzpyrene, furan, benzofuran, isobenzofuran, dibenzofuran, thiophene, benzothiophene, isobenzothiophene, dibenzothiophene; pyrrole, indole, isoindole, carbazole, pyridine, quinoline, isoquinoline, acridine, phenanthridine, benzo-5,6-quinoline, benzo-6,7-quinoline, benzo-7,8-quinoline, phenothiazine, phenoxazine, pyrazole, indazole, imidazole, benzimidazole, naphthoimidazole, phenanthroimidazole, pyridoimidazole, pyrazinoimidazole, quinoxalinoimidazole, oxazole, benzoxazole, napthooxazole, anthroxazol, phenanthroxazol, isoxazole, 1,2-thiazole, 1,3-thiazole, benzothiazole, pyridazine, benzopyridazine, pyrimidine, benzopyrimidine, 1,3,5-triazine, quinoxaline, pyrazine, phenazine, naphthyridine, carboline, benzocarboline, phenanthroline, 1,2,3-triazole, 1,2,4-triazole, benzotriazole, 1,2,3-oxadiazole, 1,2,4-oxadiazole, 1,2,5-oxadiazole, 1,2,3,4-tetrazine, purine, pteridine, indolizine and benzothiadiazole or combinations of the abovementioned groups.

[0087] As used throughout the present application, the term cyclic group may be understood in the broadest sense as any mono-, bi- or polycyclic moieties.

[0088] As used throughout the present application, the term biphenyl as a substituent may be understood in the broadest sense as ortho-biphenyl, meta-biphenyl, or para-biphenyl, wherein ortho, meta and para is defined in regard to the binding site to another chemical moiety.

[0089] As used throughout the present application, the term alkyl group may be understood in the broadest sense as any linear, branched, or cyclic alkyl substituent. In particular, the term alkyl comprises the substituents methyl (Me), ethyl (Et), n-propyl (nPr), i-propyl (iPr), cyclopropyl, n-butyl (nBu), i-butyl (tBu), s-butyl (sBu), t-butyl(tBu), cyclobutyl, 2-methylbutyl, n-pentyl, s-pentyl, t-pentyl, 2-pentyl, neo-pentyl, cyclopentyl, n-hexyl, s-hexyl, t-hexyl, 2-hexyl, 3-hexyl, neo-hexyl, cyclohexyl, 1-methylcyclopentyl, 2-methylpentyl, n-heptyl, 2-heptyl, 3-heptyl, 4-heptyl, cycloheptyl, 1-methylcyclohexyl, n-octyl, 2-ethylhexyl, cyclooctyl, 1-bicyclo[2,2,2]octyl, 2-bicyclo[2,2,2]-octyl, 2-(2,6-dimethyl)octyl, 3-(3,7-dimethyl)octyl, adamantyl, 2,2,2-trifluorethyl, 1,1-dimethyl-n-hex-1-yl, 1,1-dimethyl-n-hept-1-yl, 1,1-dimethyl-n-oct-1-yl, 1,1-dimethyl-n-dec-1-yl, 1,1-dimethyl-n-dodec-1-yl, 1,1-dimethyl-n-tetradec-1-yl, 1,1-dimethyl-n-hexadec-1-yl, 1,1-dimethyl-n-octadec-1-yl, 1,1-diethyl-n-hex-1-yl, 1,1-diethyl-n-hept-1-yl, 1,1-diethyl-n-oct-1-yl, 1,1-diethyl-n-dec-1-yl, 1,1-diethyl-n-dodec-1-yl, 1,1-diethyl-n-tetradec-1-yl, 1,1-diethyln-n-hexadec-1-yl, 1,1-diethyl-n-octadec-1-yl, 1-(n-propyl)-cyclohex-1-yl, 1-(n-butyl)-cyclohex-1-yl, 1-(n-hexyl)-cyclohex-1-yl, 1-(n-octyl)-cyclohex-1-yl and 1-(n-decyl)-cyclohex-1-yl.

[0090] As used throughout the present application, the term alkenyl comprises linear, branched, and cyclic alkenyl substituents. The term alkenyl group exemplarily comprises the substituents ethenyl, propenyl, butenyl, pentenyl, cyclopentenyl, hexenyl, cyclohexenyl, heptenyl, cycloheptenyl, octenyl, cyclooctenyl or cyclooctadienyl.

[0091] As used throughout the present application, the term alkynyl comprises linear, branched, and cyclic alkynyl substituents. The term alkynyl group exemplarily comprises ethynyl, propynyl, butynyl, pentynyl, hexynyl, heptynyl or octynyl.

[0092] As used throughout the present application the term alkoxy comprises linear, branched, and cyclic alkoxy substituents. The term alkoxy group exemplarily comprises methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, i-butoxy, s-butoxy, t-butoxy and 2-methylbutoxy.

[0093] As used throughout the present application the term thioalkoxy comprises linear, branched, and cyclic thioalkoxy substituents, in which the O of the exemplarily alkoxy groups is replaced by S.

[0094] As used throughout the present application, the terms "halogen" and "halo" may be understood in the broadest sense as being preferably fluorine, chlorine, bromine or iodine.

[0095] Whenever hydrogen (H) is mentioned herein, it could also be replaced by deuterium at each occurrence.

[0096] It is understood that when a molecular fragment is described as being a substituent or otherwise attached to another moiety, its name may be written as if it were a fragment (e.g. naphtyl, dibenzofuryl) or as if it were the whole molecule (e.g. naphthalene, dibenzofuran). As used herein, these different ways of designating a substituent or attached fragment are considered to be equivalent.

[0097] In one embodiment, the organic molecules according to the invention have an excited state lifetime of not more than 150 µs, of not more than 100 µs, in particular of not more than 50 µs, more preferably of not more than 10 µs or not more than 7 µs in a film of poly(methyl methacrylate) (PMMA) with 10 % by weight of organic molecule at room temperature.

[0098] In one embodiment of the invention, the organic molecules according to the invention represent thermally-activated delayed fluorescence (TADF) emitters, which exhibit a ΔEST value, which corresponds to the energy difference between the first excited singlet state (S1) and the first excited triplet state (T1), of less than 5000 cm-1, preferably less than 3000 cm-1, more preferably less than 1500 cm-1, even more preferably less than 1000 cm-1 or even less than 500 cm-1.

[0099] In a further embodiment of the invention, the energy level of the highest occupied molecular orbital HOMO(E) of the organic molecule according to the invention E (EHOMO(E)) is larger than -6.2 eV, preferably larger than -6.0 eV, more preferably larger than -5.9 eV, even more preferably larger than -5.8 eV, wherein EHOMO(E) is determined by cyclic voltammetry.

[0100] In a further embodiment of the invention, the energy level of the highest occupied molecular orbital HOMO(E) of the organic molecule according to the invention E (EHOMO(E)) is larger than -5.8 eV, wherein EHOMO(E) is determined by cyclic voltammetry.

[0101] In a further embodiment of the invention, the organic molecules according to the invention have an emission peak in the visible or nearest ultraviolet range, i.e., in the range of a wavelength of from 380 to 800 nm, with a full width at half maximum of less than 0.50 eV, preferably less than 0.48 eV, more preferably less than 0.45 eV, even more preferably less than 0.43 eV or even less than 0.40 eV in a film of poly(methyl methacrylate) (PMMA) with 10 % by weight of organic molecule at room temperature.

[0102] In a further embodiment of the invention, the organic molecules according to the invention have a "blue material index" (BMI), calculated by dividing the photoluminescence quantum yield (PLQY) in % by the CIEy color coordinate of the emitted light, of more than 150, in particular more than 200, preferably more than 250, more preferably of more than 300 or even more than 500. The photoluminescence quantum yield determination method applied is described in the experimental section.

[0103] Orbital and excited state energies can be determined either by means of experimental methods or by calculations employing quantum-chemical methods, in particular density functional theory calculations. The energy of the highest occupied molecular orbital EHOMO is determined by methods known to the person skilled in the art from cyclic voltammetry measurements with an accuracy of 0.1 eV. The cyclic voltammetry measurement methods are described in the experimental section. The energy of the lowest unoccupied molecular orbital ELUMO is calculated as EHOMO + Egap, wherein Egap is determined as follows: For host compounds, the onset of the emission spectrum of a film with 10 % by weight of host in poly(methyl methacrylate) (PMMA) is used as Egap, unless stated otherwise. For emitter molecules, Egap is determined as the energy at which the excitation and emission spectra of a film with 10% by weight of emitter in PMMA cross.

[0104] The energy of the first excited triplet state T1 is determined from the onset of the emission spectrum at low temperature, typically at 77 K. For host compounds, where the first excited singlet state and the lowest triplet state are energetically separated by > 0.4 eV, the phosphorescence is usually visible in a steady-state spectrum in 2-Me-THF. The triplet energy can thus be determined as the onset of the phosphorescence spectrum. For TADF emitter molecules, the energy of the first excited triplet state T1 is determined from the onset of the delayed emission spectrum at 77 K, if not otherwise stated measured in a film of PMMA with 10% by weight of emitter. Both for host and emitter compounds, the energy of the first excited singlet state S1 is determined from the onset of the emission spectrum, if not otherwise stated measured in a film of PMMA with 10% by weight of host or emitter compound.

[0105] The onset of an emission spectrum is determined by computing the intersection of the tangent to the emission spectrum with the x-axis. The tangent to the emission spectrum is set at the high-energy side of the emission band and at the point at half maximum of the maximum intensity of the emission spectrum.

[0106] A further aspect of the invention relates to a process for preparing organic molecules (with an optional subsequent reaction) according to the invention, wherein a chloro-fluoro-tri-R1-substituted phenylboronic acid is used as a reactant:



[0107] According to the invention, in the reaction for the synthesis of E0-2 a boronic acid or an equivalent boronic acid ester can be used instead of a boronic pinacol ester. Exemplary boronic acid esters or boronic acids are 2-chloro-6-fluorophenylboronic ester or acid, 2-chloro-5-fluorophenylboronic ester or acid, 2-chloro-4-fluorophenylboronic ester or acid, 3-chloro-6-fluorophenylboronic ester or acid, 3-chloro-5-fluorophenylboronic ester or acid, 3-chloro-4-fluorophenylboronic ester or acid, 4-chloro-6-fluorophenylboronic ester or acid and 4-chloro-5-fluorophenylboronic ester or acid.

[0108] According to the invention, in the reaction for the synthesis of E2 a boronic acid or an equivalent boronic acid ester can be used instead of a boronic pinacol ester. Exemplary boronic acid esters or boronic acids are 2-chloro-6-fluorophenylboronic ester or acid, 2-chloro-5-fluorophenylboronic ester or acid, 2-chloro-4-fluorophenylboronic ester or acid, 3-chloro-6-fluorophenylboronic ester or acid, 3-chloro-5-fluorophenylboronic ester or acid, 3-chloro-4-fluorophenylboronic ester or acid, 4-chloro-6-fluorophenylboronic ester or acid and 4-chloro-5-fluorophenylboronic ester or acid.

[0109] According to the invention, in the reaction for the synthesis of Z via Synthesis route II a boronic acid or an equivalent boronic acid ester can be used instead of a boronic pinacol ester. Exemplary boronic acid esters or boronic acids are 2-fluoro-3-pyridineboronic ester or acid, 4-fluoro-3-pyridineboronic ester or acid, 5-fluoro-3-pyridineboronic ester or acid, 6-fluoro-3-pyridineboronic ester or acid, 3-fluoro-2-pyridineboronic ester or acid, 4-fluoro-2-pyridineboronic ester or acid, 5-fluoro-2-pyridineboronic ester or acid, 6-fluoro-2-pyridineboronic ester or acid, 2-fluoro-4-pyridineboronic ester or acid, 3-fluoro-4-pyridineboronic ester or acid.

[0110] Typically, Pd2(dba)3 (tris(dibenzylideneacetone)dipalladium(0); CAS 51364-51-3), Pd(dppf)Cl2 ([1,1'-Bis(diphenylphosphino)ferrocene]palladium(II) dichloride; CAS 72287-26-4), and Pd(PPh3)4 (Tetrakis(triphenylphosphine)palladium(0); CAS 14221-01-3) are used as a Pd catalyst, but alternatives are known in the art. For example, the ligand may be selected from the group consisting of S-Phos ([2-dicyclohexylphoshino-2',6'-dimethoxy-1,1'-biphenyl]), X-Phos (2-(dicyclohexylphosphino)-2",4",6"-triisopropylbiphenyl), and P(Cy)3 (tricyclohexylphosphine). The salt is, for example, selected from tribasic potassium phosphate and potassium acetate and the solvent can be a pure solvent, such as toluene or dioxane, or a mixture, such as toluene/dioxane/water or dioxane/toluene. A person of skill in the art can determine which Pd catalyst, ligand, salt and solvent combination will result in high reaction yields.

[0111] For the reaction of a nitrogen heterocycle in a nucleophilic aromatic substitution with an aryl halide, preferably an aryl fluoride, typical conditions include the use of a base, such as tribasic potassium phosphate or sodium hydride, for example, in an aprotic polar solvent, such as dimethyl sulfoxide (DMSO) or N,N-dimethylformamide (DMF), for example.

[0112] An alternative synthesis route comprises the introduction of a nitrogen heterocycle via copper- or palladium-catalyzed coupling to an aryl halide or aryl pseudohalide, preferably an aryl bromide, an aryl iodide, aryl triflate or an aryl tosylate.

[0113] A further aspect of the invention relates to the use of an organic molecule according to the invention as a luminescent emitter or as an absorber, and/or as host material and/or as electron transport material, and/or as hole injection material, and/or as hole blocking material in an optoelectronic device, in particular as a luminescent emitter.

[0114] The optoelectronic device may be understood in the broadest sense as any device based on organic materials that is suitable for emitting light in the visible or nearest ultraviolet (UV) range, i.e., in the range of a wavelength of from 380 to 800 nm. More preferably, the optoelectronic device may be able to emit light in the visible range, i.e., of from 400 to 800 nm.

[0115] In the context of such use, the optoelectronic device is more particularly selected from the group consisting of:
  • organic light-emitting diodes (OLEDs),
  • light-emitting electrochemical cells,
  • OLED sensors, especially in gas and vapor sensors not hermetically externally shielded,
  • organic diodes,
  • organic solar cells,
  • organic transistors,
  • organic field-effect transistors,
  • organic lasers, and
  • down-conversion elements.


[0116] In a preferred embodiment in the context of such use, the optoelectronic device is a device selected from the group consisting of an organic light emitting diode (OLED), a light emitting electrochemical cell (LEC), and a light-emitting transistor.

[0117] In the case of the use, the fraction of the organic molecule according to the invention in the emission layer in an optoelectronic device, more particularly in OLEDs, is 1 % to 99 % by weight, more particularly 5 % to 80 % by weight. In an alternative embodiment, the proportion of the organic molecule in the emission layer is 100 % by weight.

[0118] In one embodiment, the light-emitting layer comprises not only the organic molecules according to the invention but also a host material whose triplet (T1) and singlet (S1) energy levels are energetically higher than the triplet (T1) and singlet (S1) energy levels of the organic molecule.

[0119] A further aspect of the invention relates to a composition comprising or consisting of:
  1. (a) at least one organic molecule according to the invention, in particular in the form of an emitter and/or a host, and
  2. (b) one or more emitter and/or host materials, which differ from the organic molecule according to the invention and
  3. (c) optional one or more dyes and/or one or more solvents.


[0120] In one embodiment, the light-emitting layer EML comprises or (essentially) consists of a composition comprising or consisting of:
  1. (a) at least one organic molecule according to the invention, in particular in the form of an emitter and/or a host, and
  2. (b) one or more emitter and/or host materials, which differ from the organic molecule according to the invention and
  3. (c) optional one or more dyes and/or one or more solvents.


[0121] Particularly preferably the light-emitting layer EML comprises or (essentially) consists of a composition comprising or consisting of:
  1. (i) 1-50 % by weight, preferably 5-40 % by weight, in particular 10-30 % by weight, of one or more organic molecules according to the invention E;
  2. (ii) 5-99 % by weight, preferably 30-94.9 % by weight, in particular 40-89% by weight, of at least one host compound H; and
  3. (iii) optionally 0-94 % by weight, preferably 0.1-65 % by weight, in particular 1-50 % by weight, of at least one further host compound D with a structure differing from the structure of the molecules according to the invention; and
  4. (iv) optionally 0-94 % by weight, preferably 0-65 % by weight, in particular 0-50 % by weight, of a solvent; and
  5. (v) optionally 0-30 % by weight, in particular 0-20 % by weight, preferably 0-5 % by weight, of at least one further emitter molecule F with a structure differing from the structure of the molecules according to the invention.


[0122] Preferably, energy can be transferred from the host compound H to the one or more organic molecules according to the invention E, in particular transferred from the first excited triplet state T1(H) of the host compound H to the first excited triplet state T1(E) of the one or more organic molecules according to the invention E and/ or from the first excited singlet state S1(H) of the host compound H to the first excited singlet state S1(E) of the one or more organic molecules according to the invention E.

[0123] In a further embodiment, the light-emitting layer EML comprises or (essentially) consists of a composition comprising or consisting of:
  1. (i) 1-50 % by weight, preferably 5-40 % by weight, in particular 10-30 % by weight, of one organic molecule according to the invention E;
  2. (ii) 5-99 % by weight, preferably 30-94.9 % by weight, in particular 40-89% by weight, of one host compound H; and
  3. (iii) optionally, 0-94 % by weight, preferably 0.1-65 % by weight, in particular 1-50 % by weight, of at least one further host compound D with a structure differing from the structure of the molecules according to the invention; and
  4. (iv) optionally, 0-94 % by weight, preferably 0-65 % by weight, in particular 0-50 % by weight, of a solvent; and
  5. (v) optionally, 0-30 % by weight, in particular 0-20 % by weight, preferably 0-5 % by weight, of at least one further emitter molecule F with a structure differing from the structure of the molecules according to the invention.


[0124] In one embodiment, the host compound H has a highest occupied molecular orbital HOMO(H) having an energy EHOMO(H) in the range of from -5 to -6.5 eV and the at least one further host compound D has a highest occupied molecular orbital HOMO(D) having an energy EHOMO(D), wherein EHOMO(H) > EHOMO(D).

[0125] In a further embodiment, the host compound H has a lowest unoccupied molecular orbital LUMO(H) having an energy ELUMO(H) and the at least one further host compound D has a lowest unoccupied molecular orbital LUMO(D) having an energy ELUMO(D), wherein ELUMO(H) > ELUMO(D).

[0126] In one embodiment, the host compound H has a highest occupied molecular orbital HOMO(H) having an energy EHOMO(H) and a lowest unoccupied molecular orbital LUMO(H) having an energy ELUMO(H), and

the at least one further host compound D has a highest occupied molecular orbital HOMO(D) having an energy EHOMO(D) and a lowest unoccupied molecular orbital LUMO(D) having an energy ELUMO(D),

the organic molecule according to the invention E has a highest occupied molecular orbital HOMO(E) having an energy EHOMO(E) and a lowest unoccupied molecular orbital LUMO(E) having an energy ELUMO(E),

wherein
EHOMO(H) > EHOMO(D) and the difference between the energy level of the highest occupied molecular orbital HOMO(E) of the organic molecule according to the invention E (EHOMO(E)) and the energy level of the highest occupied molecular orbital HOMO(H) of the host compound H (EHOMO(H)) is between -0.5 eV and 0.5 eV, more preferably between -0.3 eV and 0.3 eV, even more preferably between -0.2 eV and 0.2 eV or even between -0.1 eV and 0.1 eV; and ELUMO(H) > ELUMO(D) and the difference between the energy level of the lowest unoccupied molecular orbital LUMO(E) of the organic molecule according to the invention E (ELUMO(E)) and the lowest unoccupied molecular orbital LUMO(D) of the at least one further host compound D (ELUMO(D)) is between -0.5 eV and 0.5 eV, more preferably between -0.3 eV and 0.3 eV, even more preferably between -0.2 eV and 0.2 eV or even between -0.1 eV and 0.1 eV.

[0127] In a further aspect, the invention relates to an optoelectronic device comprising an organic molecule or a composition of the type described herein, more particularly in the form of a device selected from the group consisting of organic light-emitting diode (OLED), light-emitting electrochemical cell, OLED sensor (particularly gas and vapor sensors not hermetically externally shielded), organic diode, organic solar cell, organic transistor, organic field-effect transistor, organic laser and down-conversion element.

[0128] In a preferred embodiment, the optoelectronic device is a device selected from the group consisting of an organic light emitting diode (OLED), a light emitting electrochemical cell (LEC), and a light-emitting transistor.

[0129] In one embodiment of the optoelectronic device of the invention, the organic molecule according to the invention E is used as emission material in a light-emitting layer EML.

[0130] In one embodiment of the optoelectronic device of the invention the light-emitting layer EML consists of the composition according to the invention described here.

[0131] For example, when the optoelectronic device is an OLED, it may exhibit the following layer structure:
  1. 1. substrate
  2. 2. anode layer A
  3. 3. hole injection layer, HIL
  4. 4. hole transport layer, HTL
  5. 5. electron blocking layer, EBL
  6. 6. emitting layer, EML
  7. 7. hole blocking layer, HBL
  8. 8. electron transport layer, ETL
  9. 9. electron injection layer, EIL
  10. 10. cathode layer,
wherein the OLED comprises each layer only optionally, except for the EML, which is mandatory. In some embodiments, different layers may be merged and the OLED may comprise more than one layer of each layer type as defined above.

[0132] Furthermore, the optoelectronic device may optionally comprise one or more protective layers protecting the device from damaging exposure to harmful species in the environment including, exemplarily moisture, vapor and/or gases.

[0133] In one embodiment of the invention, the optoelectronic device is an OLED, which exhibits the following inverted layer structure:
  1. 1. substrate
  2. 2. cathode layer
  3. 3. electron injection layer, EIL
  4. 4. electron transport layer, ETL
  5. 5. hole blocking layer, HBL
  6. 6. emitting layer, B
  7. 7. electron blocking layer, EBL
  8. 8. hole transport layer, HTL
  9. 9. hole injection layer, HIL
  10. 10. anode layer A
wherein the OLED with an inverted layer structure comprises each layer other than the emitting layer B only optionally. In some embodiments, different layers may be merged and the OLED may comprise more than one layer of each layer types defined above.

[0134] In one embodiment of the invention, the optoelectronic device is an OLED, which may exhibit stacked architecture. In this architecture, contrary to the typical arrangement, where the OLEDs are placed side by side, the individual units are stacked on top of each other. Blended light may be generated with OLEDs exhibiting a stacked architecture, in particular white light may be generated by stacking blue, green and red OLEDs. Furthermore, the OLED exhibiting a stacked architecture may optionally comprise a charge generation layer (CGL), which is typically located between two OLED subunits and typically consists of a n-doped and p-doped layer with the n-doped layer of one CGL being typically located closer to the anode layer.

[0135] In one embodiment of the invention, the optoelectronic device is an OLED, which comprises two or more emission layers between anode and cathode. In particular, this so-called tandem OLED comprises three emission layers, wherein one emission layer emits red light, one emission layer emits green light and one emission layer emits blue light, and optionally may comprise further layers such as charge generation layers, blocking or transporting layers between the individual emission layers. In a further embodiment, the emission layers are adjacently stacked. In a further embodiment, the tandem OLED comprises a charge generation layer between each two emission layers. In addition, adjacent emission layers or emission layers separated by a charge generation layer may be merged.

[0136] The substrate may be formed by any material or composition of materials. Most frequently, glass slides are used as substrates. Alternatively, thin metal layers (e.g., copper, gold, silver or aluminum films) or plastic films or slides may be used. This may allow a higher degree of flexibility. The anode layer A is mostly composed of materials allowing to obtain an (essentially) transparent film. As at least one of both electrodes should be (essentially) transparent in order to allow light emission from the OLED, either the anode layer A or the cathode layer C is transparent. Preferably, the anode layer A comprises a large content or even consists of transparent conductive oxides (TCOs). Such anode layer A may exemplarily comprise indium tin oxide, aluminum zinc oxide, fluorine doped tin oxide, indium zinc oxide, PbO, SnO, zirconium oxide, molybdenum oxide, vanadium oxide, wolfram oxide, graphite, doped Si, doped Ge, doped GaAs, doped polyaniline, doped polypyrrol and/or doped polythiophene.

[0137] Particularly preferably, the anode layer A (essentially) consists of indium tin oxide (ITO) (e.g., (InO3)0.9(SnO2)0.1). The roughness of the anode layer A caused by the transparent conductive oxides (TCOs) may be compensated by using a hole injection layer (HIL). Further, the HIL may facilitate the injection of quasi charge carriers (i.e., holes) in that the transport of the quasi charge carriers from the TCO to the hole transport layer (HTL) is facilitated. The hole injection layer (HIL) may comprise poly-3,4-ethylendioxy thiophene (PEDOT), polystyrene sulfonate (PSS), MoO2, V2O5, CuPC or Cul, in particular a mixture of PEDOT and PSS. The hole injection layer (HIL) may also prevent the diffusion of metals from the anode layer A into the hole transport layer (HTL). The HIL may exemplarily comprise PEDOT:PSS (poly-3,4-ethylendioxy thiophene: polystyrene sulfonate), PEDOT (poly-3,4-ethylendioxy thiophene), mMTDATA (4,4',4"-tris[phenyl(m-tolyl)amino]triphenylamine), Spiro-TAD (2,2',7,7'-tetrakis(n,n-diphenylamino)-9,9'-spirobifluorene), DNTPD (N1,N1'-(biphenyl-4,4'-diyl)bis(N1-phenyl-N4,N4-di-m-tolylbenzene-1,4-diamine), NPB (N,N'-nis-(1-naphthalenyl)-N,N'-bisphenyl-(1,1'-biphenyl)-4,4'-diamine), NPNPB (N,N'-diphenyl-N,N'-di-[4-(N,N-diphenyl-amino)phenyl]benzidine), MeO-TPD (N,N,N',N'-tetrakis(4-methoxyphenyl)benzidine), HAT-CN (1,4,5,8,9,11-hexaazatriphenylen-hexacarbonitrile) and/or Spiro-NPD (N,N'-diphenyl-N,N'-bis-(1-naphthyl)-9,9'-spirobifluorene-2,7-diamine).

[0138] Adjacent to the anode layer A or hole injection layer (HIL) typically a hole transport layer (HTL) is located. Herein, any hole transport compound may be used. Exemplarily, electron-rich heteroaromatic compounds such as triarylamines and/or carbazoles may be used as hole transport compound. The HTL may decrease the energy barrier between the anode layer A and the light-emitting layer EML. The hole transport layer (HTL) may also be an electron blocking layer (EBL). Preferably, hole transport compounds bear comparably high energy levels of their triplet states T1. Exemplarily the hole transport layer (HTL) may comprise a star-shaped heterocycle such as tris(4-carbazoyl-9-ylphenyl)amine (TCTA), poly-TPD (poly(4-butylphenyl-diphenyl-amine)), [alpha]-NPD (poly(4-butylphenyl-diphenyl-amine)), TAPC (4,4'-cyclohexyliden-bis[N,N-bis(4-methylphenyl)benzenamine]), 2-TNATA (4,4',4"-tris[2-naphthyl(phenyl)amino]triphenylamine), Spiro-TAD, DNTPD, NPB, NPNPB, MeO-TPD, HAT-CN and/or TrisPcz (9,9'-diphenyl-6-(9-phenyl-9H-carbazol-3-yl)-9H,9'H-3,3'-bicarbazole). In addition, the HTL may comprise a p-doped layer, which may be composed of an inorganic or organic dopant in an organic hole-transporting matrix. Transition metal oxides such as vanadium oxide, molybdenum oxide or tungsten oxide may exemplarily be used as inorganic dopant. Tetrafluorotetracyanoquinodimethane (F4-TCNQ), copper-pentafluorobenzoate (Cu(I)pFBz) or transition metal complexes may exemplarily be used as organic dopant.

[0139] The EBL may exemplarily comprise mCP (1,3-bis(carbazol-9-yl)benzene), TCTA, 2-TNATA, mCBP (3,3-di(9H-carbazol-9-yl)biphenyl), tris-Pcz, CzSi (9-(4-tert-Butylphenyl)-3,6-bis(triphenylsilyl)-9H-carbazole), and/or DCB (N,N'-dicarbazolyl-1,4-dimethylbenzene).

[0140] Adjacent to the hole transport layer (HTL), typically, the light-emitting layer EML is located. The light-emitting layer EML comprises at least one light emitting molecule. Particularly, the EML comprises at least one light emitting molecule according to the invention E. In one embodiment, the light-emitting layer comprises only the organic molecules according to the invention E. Typically, the EML additionally comprises one or more host materials H. Exemplarily, the host material H is selected from CBP (4,4'-Bis-(N-carbazolyl)-biphenyl), mCP, mCBP Sif87 (dibenzo[b,d]thiophen-2-yltriphenylsilane), CzSi, SiMCP (3,5-Di(9H-carbazol-9-yl)phenyl]triphenylsilane), Sif88 (dibenzo[b,d]thiophen-2-yl)diphenylsilane), DPEPO (bis[2-(diphenylphosphino)phenyl] ether oxide), 9-[3-(dibenzofuran-2-yl)phenyl]-9H-carbazole, 9-[3-(dibenzofuran-2-yl)phenyl]-9H-carbazole, 9-[3-(dibenzothiophen-2-yl)phenyl]-9H-carbazole, 9-[3,5-bis(2-dibenzofuranyl)phenyl]-9H-carbazole, 9-[3,5-bis(2-dibenzothiophenyl)phenyl]-9H-carbazole, T2T (2,4,6-tris(biphenyl-3-yl)-1,3,5-triazine), T3T (2,4,6-tris(triphenyl-3-yl)-1,3,5-triazine) and/or TST (2,4,6-tris(9,9'-spirobifluorene-2-yl)-1,3,5-triazine). The host material H typically should be selected to exhibit first triplet (T1) and first singlet (S1) energy levels, which are energetically higher than the first triplet (T1) and first singlet (S1) energy levels of the organic molecule.

[0141] In one embodiment of the invention, the EML comprises a so-called mixed-host system with at least one hole-dominant host and one electron-dominant host. In a particular embodiment, the EML comprises exactly one light emitting molecule according to the invention E and a mixed-host system comprising T2T as electron-dominant host and a host selected from CBP, mCP, mCBP, 9-[3-(dibenzofuran-2-yl)phenyl]-9H-carbazole, 9-[3-(dibenzofuran-2-yl)phenyl]-9H-carbazole, 9-[3-(dibenzothiophen-2-yl)phenyl]-9H-carbazole, 9-[3,5-bis(2-dibenzofuranyl)phenyl]-9H-carbazole and 9-[3,5-bis(2-dibenzothiophenyl)phenyl]-9H-carbazole as hole-dominant host. In a further embodiment the EML comprises 50-80 % by weight, preferably 60-75 % by weight of a host selected from CBP, mCP, mCBP, 9-[3-(dibenzofuran-2-yl)phenyl]-9H-carbazole, 9-[3-(dibenzofuran-2-yl)phenyl]-9H-carbazole, 9-[3-(dibenzothiophen-2-yl)phenyl]-9H-carbazole, 9-[3,5-bis(2-dibenzofuranyl)phenyl]-9H-carbazole and 9-[3,5-bis(2-dibenzothiophenyl)phenyl]-9H-carbazole; 10-45 % by weight, preferably 15-30 % by weight of T2T and 5-40 % by weight, preferably 10-30 % by weight of light emitting molecule according to the invention.

[0142] Adjacent to the light-emitting layer EML an electron transport layer (ETL) may be located. Herein, any electron transporter may be used. Exemplarily, electron-poor compounds such as, e.g., benzimidazoles, pyridines, triazoles, oxadiazoles (e.g., 1,3,4-oxadiazole), phosphinoxides and sulfone, may be used. An electron transporter may also be a star-shaped heterocycle such as 1,3,5-tri(1-phenyl-1H-benzo[d]imidazol-2-yl)phenyl (TPBi). The ETL may comprise NBphen (2,9-bis(naphthalen-2-yl)-4,7-diphenyl-1,10-phenanthroline), Alq3 (Aluminum-tris(8-hydroxyquinoline)), TSPO1 (diphenyl-4-triphenylsilylphenyl-phosphinoxide), BPyTP2 (2,7-di(2,2'-bipyridin-5-yl)triphenyle), Sif87 (dibenzo[b,d]thiophen-2-yltriphenylsilane), Sif88 (dibenzo[b,d]thiophen-2-yl)diphenylsilane), BmPyPhB (1,3-bis[3,5-di(pyridin-3-yl)phenyl]benzene) and/or BTB (4,4'-bis-[2-(4,6-diphenyl-1,3,5-triazinyl)]-1,1'-biphenyl). Optionally, the ETL may be doped with materials such as Liq. The electron transport layer (ETL) may also block holes or a holeblocking layer (HBL) is introduced.
The HBL may, for example, comprise BCP (2,9-dimethyl-4,7-diphenyl-1,10-phenanthroline = Bathocuproine), BAlq (bis(8-hydroxy-2-methylquinoline)-(4-phenylphenoxy)aluminum), NBphen (2,9-bis(naphthalen-2-yl)-4,7-diphenyl-1,10-phenanthroline), Alq3 (Aluminum-tris(8-hydroxyquinoline)), TSPO1 (diphenyl-4-triphenylsilylphenyl-phosphinoxide), T2T (2,4,6-tris(biphenyl-3-yl)-1,3,5-triazine), T3T (2,4,6-tris(triphenyl-3-yl)-1,3,5-triazine), TST (2,4,6-tris(9,9'-spirobifluorene-2-yl)-1,3,5-triazine), and/or TCB/TCP (1,3,5-tris(N-carbazolyl)benzol/ 1,3,5-tris(carbazol)-9-yl) benzene).

[0143] Adjacent to the electron transport layer (ETL), a cathode layer C may be located. Exemplarily, the cathode layer C may comprise or may consist of a metal (e.g., Al, Au, Ag, Pt, Cu, Zn, Ni, Fe, Pb, LiF, Ca, Ba, Mg, In, W, or Pd) or a metal alloy. For practical reasons, the cathode layer may also consist of (essentially) non-transparent metals such as Mg, Ca or Al. Alternatively or additionally, the cathode layer C may also comprise graphite and or carbon nanotubes (CNTs). Alternatively, the cathode layer C may also consist of nanoscalic silver wires.

[0144] An OLED may further, optionally, comprise a protection layer between the electron transport layer (ETL) and the cathode layer C (which may be designated as electron injection layer (EIL)). This layer may comprise lithium fluoride, cesium fluoride, silver, Liq (8-hydroxyquinolinolatolithium), Li2O, BaF2, MgO and/or NaF.

[0145] Optionally, also the electron transport layer (ETL) and/or a hole blocking layer (HBL) may comprise one or more host compounds H.

[0146] In order to modify the emission spectrum and/or the absorption spectrum of the light-emitting layer EML further, the light-emitting layer EML may further comprise one or more further emitter molecules F. Such an emitter molecule F may be any emitter molecule known in the art. Preferably such an emitter molecule F is a molecule with a structure differing from the structure of the molecules according to the invention E. The emitter molecule F may optionally be a TADF emitter. Alternatively, the emitter molecule F may optionally be a fluorescent and/or phosphorescent emitter molecule which is able to shift the emission spectrum and/or the absorption spectrum of the light-emitting layer EML. Exemplarily, the triplet and/or singlet excitons may be transferred from the emitter molecule according to the invention E to the emitter molecule F before relaxing to the ground state S0 by emitting light typically red-shifted in comparison to the light emitted by emitter molecule E. Optionally, the emitter molecule F may also provoke two-photon effects (i.e., the absorption of two photons of half the energy of the absorption maximum).

[0147] Optionally, an optoelectronic device (e.g., an OLED) may exemplarily be an essentially white optoelectronic device. Exemplarily such white optoelectronic device may comprise at least one (deep) blue emitter molecule and one or more emitter molecules emitting green and/or red light. Then, there may also optionally be energy transmittance between two or more molecules as described above.

[0148] As used herein, if not defined more specifically in the particular context, the designation of the colors of emitted and/or absorbed light is as follows:
violet: wavelength range of >380-420 nm;
deep blue: wavelength range of >420-480 nm;
sky blue: wavelength range of >480-500 nm;
green: wavelength range of >500-560 nm;
yellow: wavelength range of >560-580 nm;
orange: wavelength range of >580-620 nm;
red: wavelength range of >620-800 nm.


[0149] With respect to emitter molecules, such colors refer to the emission maximum. Therefore, exemplarily, a deep blue emitter has an emission maximum in the range of from >420 to 480 nm, a sky blue emitter has an emission maximum in the range of from >480 to 500 nm, a green emitter has an emission maximum in a range of from >500 to 560 nm, a red emitter has an emission maximum in a range of from >620 to 800 nm.

[0150] A deep blue emitter may preferably have an emission maximum of below 480 nm, more preferably below 470 nm, even more preferably below 465 nm or even below 460 nm. It will typically be above 420 nm, preferably above 430 nm, more preferably above 440 nm or even above 450 nm.

[0151] Accordingly, a further aspect of the present invention relates to an OLED, which exhibits an external quantum efficiency at 1000 cd/m2 of more than 8 %, more preferably of more than 10 %, more preferably of more than 13 %, even more preferably of more than 15 % or even more than 20 % and/or exhibits an emission maximum between 420 nm and 500 nm, preferably between 430 nm and 490 nm, more preferably between 440 nm and 480 nm, even more preferably between 450 nm and 470 nm and/or exhibits a LT80 value at 500 cd/m2 of more than 100 h, preferably more than 200 h, more preferably more than 400 h, even more preferably more than 750 h or even more than 1000 h. Accordingly, a further aspect of the present invention relates to an OLED, whose emission exhibits a CIEy color coordinate of less than 0.45, preferably less than 0.30, more preferably less than 0.20 or even more preferably less than 0.15 or even less than 0.10.

[0152] A further aspect of the present invention relates to an OLED, which emits light at a distinct color point. According to the present invention, the OLED emits light with a narrow emission band (small full width at half maximum (FWHM)). In one aspect, the OLED according to the invention emits light with a FWHM of the main emission peak of less than 0.50 eV, preferably less than 0.48 eV, more preferably less than 0.45 eV, even more preferably less than 0.43 eV or even less than 0.40 eV.

[0153] A further aspect of the present invention relates to an OLED, which emits light with CIEx and CIEy color coordinates close to the CIEx and CIEy color coordinates of the primary color blue (CIEx = 0.131 and CIEy = 0.046) as defined by ITU-R Recommendation BT.2020 (Rec. 2020) and thus is suited for the use in Ultra High Definition (UHD) displays, e.g. UHD-TVs. Accordingly, a further aspect of the present invention relates to an OLED, whose emission exhibits a CIEx color coordinate of between 0.02 and 0.30, preferably between 0.03 and 0.25, more preferably between 0.05 and 0.20 or even more preferably between 0.08 and 0.18 or even between 0.10 and 0.15 and/ or a a CIEy color coordinate of between 0.00 and 0.45, preferably between 0.01 and 0.30, more preferably between 0.02 and 0.20 or even more preferably between 0.03 and 0.15 or even between 0.04 and 0.10.

[0154] In a further aspect, the invention relates to a method for producing an optoelectronic component. In this case an organic molecule of the invention is used.

[0155] The optoelectronic device, in particular the OLED according to the present invention can be produced by any means of vapor deposition and/or liquid processing. Accordingly, at least one layer is
  • prepared by means of a sublimation process,
  • prepared by means of an organic vapor phase deposition process,
  • prepared by means of a carrier gas sublimation process,
  • solution processed, or
  • printed.


[0156] Another aspect of the present invention relates to a Method for producing an optoelectronic device, wherein an organic molecule or composition according to the invention is used, in particular comprising the processing of the organic molecule or of the composition by a vacuum evaporation method or from a solution.

[0157] Further steps used to produce the optoelectronic device, in particular the OLED according to the present invention, comprise depositing different layers individually and successively on a suitable substrate by means of subsequent deposition processes. The individual layers may be deposited using the same or differing deposition methods.

[0158] Vapor deposition processes comprise, for example, thermal (co)evaporation, chemical vapor deposition and physical vapor deposition. For active matrix OLED display, an AMOLED backplane is used as substrate. The individual layer may be processed from solutions or dispersions employing adequate solvents. Solution deposition process exemplarily comprise spin coating, dip coating and jet printing. Liquid processing may optionally be carried out in an inert atmosphere (e.g., in a nitrogen atmosphere) and the solvent may optionally be completely or partially removed by means known in the state of the art.

Examples



[0159] 


General procedure for Synthesis route I - AAV-1-1



[0160] 



[0161] E0-0 (1.2 equivalents), E0-1 (1.00 equivalents), Pd(dppf)Cl2 ([1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride; CAS 72287-26-4; 0.05 equivalents) and potassium acetate (2.5 equivalents) are stirred under nitrogen atmosphere in a dioxane/water mixture (ratio of 10:1) at 110 °C for 20 h. Subsequently, active carbon and Celite® (kieselgur) are added to the mixture and stirred for 20 min. The reaction mixture is hot filtered and the residue washed with dioxane. The reaction mixture is poured into 300 mL of a saturated sodium chloride solution and extracted with ethyl acetate. The combined organic phases are washed with saturated sodium chloride solution, dried over Na2SO4 and the solvent is evaporated under reduced pressure. The crude solid is hot washed with EtOH to yield a white solid.

General procedure for Synthesis route I - AAV-1-2



[0162] 



[0163] E0-2 (1.00 equivalents), bis(pinacolato)diboron (1.2 equivalents), Pd2dba3 (tris(dibenzylideneacetone)dipalladium; CAS 51364-51-3; 0.02 equivalents), SPhos (2-dicyclohexylphosphino-2',6'-dimethoxy-1,1'-biphenyl, CAS 657408-07-6, 0,04 equivalents) and potassium phosphate tribasic (2.5 equivalents) are stirred under nitrogen atmosphere in a dioxane at 100 °C for 20 h. Subsequently, the reaction mixture is hot filtered and the residue washed with toluene. The reaction mixture is poured into 300 mL of a saturated sodium chloride solution and extracted with ethyl acetate. The combined organic phases are washed with saturated sodium chloride solution, dried over Na2SO4 and the solvent is evaporated under reduced pressure.

General procedure for Synthesis route I - AAV-1-3



[0164] 



[0165] E1-1 (1.00 equivalents), E1 (3.00 equivalents), Pd2(dba)3 (tris(dibenzylideneacetone)dipalladium(0); CAS 51364-51-3; 0.04 equivalents) SPhos (2-dicyclohexylphosphino-2',6'-dimethoxy-1,1'-biphenyl, CAS 657408-07-6, 0,04 equivalents) and potassium phosphate tribasic (5.0 equivalents) are stirred under nitrogen atmosphere in a toluene/water mixture (ratio of 10:1) at 110 °C for 20 h. Subsequently, the reaction mixture is hot filtered and the residue washed with toluene. The reaction mixture is poured into 300 mL of a saturated sodium chloride solution and extracted with ethyl acetate. The combined organic phases are washed with saturated sodium chloride solution, dried over Na2SO4 and the solvent is evaporated under reduced pressure.

[0166] The residue is purified by chromatography (or by recrystallization or, alternatively, is stirred in hot ethanol and filtered) and Z is obtained as a solid.

General procedure for Synthesis route II - AAV2-1:



[0167] 



[0168] E1-1 (1.00 equivalents), E0-0 (3.00 equivalents), Pd(PPh3)4 (tetrakis(triphenylphosphine)palladium; CAS 14221-01-3; 0.04 equivalents) and potassium carbonate (4.0 equivalents) are stirred under nitrogen atmosphere in a toluene/water mixture (ratio of 10:1) at 110 °C for 20 h. Subsequently, the reaction mixture is hot filtered and the residue washed with toluene. The reaction mixture is poured into 300 mL of a saturated sodium chloride solution and extracted with ethyl acetate. The combined organic phases are washed with saturated sodium chloride solution, dried over Na2SO4 and the solvent is evaporated under reduced pressure.

[0169] The residue is purified by chromatography (or by recrystallization or, alternatively, is stirred in hot ethanol and filtered) and E2 is obtained as a solid.

General procedure for Synthesis route II - AAV2-2:



[0170] 



[0171] E2 (1.00 equivalents), E2-1 (2.3 equivalents), ([tris(dibenzylideneacetone)dipalladium(0)]; 0.01 equivalents), SPhos (0.04 equivalents) and potassium phosphate tribasic (5.0 equivalents) are stirred under nitrogen atmosphere in a toluene/water mixture (ratio of 10:1) at 110 °C for 20 h. Subsequently, the reaction mixture is hot filtered and the residue washed with toluene.

General procedure for synthesis AAV3:



[0172] 



[0173] Z (1.0 equivalent), the corresponding donor molecule D-H (4.4 equivalents) and tribasic potassium phosphate (8.0 equivalents) are suspended under nitrogen atmosphere in DMSO and stirred at 130 °C (20 h).

[0174] Subsequently, the reaction mixture is poured onto ice and the precipitate is filtered and washed with water. The solid is then dissolved in dichloromethane, dried over Na2SO4 and the solvent is evaporated under reduced pressure. The crude product is purified by recrystallization or by flash chromatography. The product is obtained as a solid.

[0175] In particular, the donor molecule D-H is a 3,6-substituted carbazole (e.g., 3,6-dimethylcarbazole, 3,6-diphenylcarbazole, 3,6-di-tert-butylcarbazole), a 2,7-substituted carbazole (e.g., 2,7-dimethylcarbazole, 2,7-diphenylcarbazole, 2,7-di-tert-butylcarbazole), a 1,8-substituted carbazole (e.g., 1,8-dimethylcarbazole, 1,8-diphenylcarbazole, 1,8-di-tert-butylcarbazole), a 1-substituted carbazole (e.g., 1-methylcarbazole, 1-phenylcarbazole, 1-tert-butylcarbazole), a 2-substituted carbazole (e.g., 2-methylcarbazole, 2-phenylcarbazole, 2-tert-butylcarbazole), or a 3-substituted carbazole (e.g., 3-methylcarbazole, 3-phenylcarbazole, 3-tert-butylcarbazole).

[0176] For example, a halogen-substituted carbazole, particularly 3-bromocarbazole, can be used as D-H.
In a subsequent reaction, a boronic acid ester functional group or boronic acid functional group may be exemplarily introduced at the position of the one or more halogen substituents, which was introduced via D-H, to yield the corresponding carbazol-3-ylboronic acid ester or carbazol-3-ylboronic acid, e.g., via the reaction with bis(pinacolato)diboron (CAS No. 73183-34-3). Subsequently, one or more substituents Ra may be introduced in place of the boronic acid ester group or the boronic acid group via a coupling reaction with the corresponding halogenated reactant Ra-Hal, preferably Ra-Cl and Ra-Br.
Alternatively, one or more substituents Ra may be introduced at the position of the one or more halogen substituents, which was introduced via D-H, via the reaction with a boronic acid of the substituent Ra [Ra-B(OH)2] or a corresponding boronic acid ester.

[0177] In particular, E0-0 is 2-chloro-6-fluorophenylboronic ester or acid, 2-chloro-5-fluorophenylboronic ester or acid, 2-chloro-4-fluorophenylboronic ester or acid, 3-chloro-6-fluorophenylboronic ester or acid, 3-chloro-5-fluorophenylboronic ester or acid, 3-chloro-4-fluorophenylboronic ester or acid, 4-chloro-6-fluorophenylboronic ester or acid and 4-chloro-5-fluorophenylboronic ester or acid.

[0178] In particular, E0-1 is 2-chloro-3-fluoropyridine, 2-chloro-4-fluoropyridine, 2-chloro-5-fluoropyridine, 3-chloro-4-fluoropyridine, 3-chloro-5-fluoropyridine, 5-chloro-2-fluoropyridine, 4-chloro-3-fluoropyridine and 4-chloro-2-fluoropyridine.

[0179] In particular, E1-1 is a 2,4-dichloro-6-phenyl-1,3,5-triazine, a 4,6-dichloro-2-phenyl-1,3-pyrimidine or a 2,6-dichloro-4-phenyl-1,3-pyrimidine.

[0180] In particular, E2-1 is 3-fluoropyridine-2-boronic acid pinacol ester, 4-fluoropyridine-2-boronic acid pinacol ester, 5-fluoropyridine-2-boronic acid pinacol ester, 4-fluoropyridine-3-boronic acid pinacol ester, 5-fluoropyridine-3-boronic acid pinacol ester, 2-fluoropyridine-5-boronic acid pinacol ester, 3-fluoropyridine-4-boronic acid pinacol ester and 2-fluoropyridine-4-boronic acid pinacol ester.

Cyclic voltammetry



[0181] Cyclic voltammograms are measured from solutions having concentration of 10-3 mol/L of the organic molecules in dichloromethane or a suitable solvent and a suitable supporting electrolyte (e.g. 0.1 mol/L of tetrabutylammonium hexafluorophosphate). The measurements are conducted at room temperature under nitrogen atmosphere with a three-electrode assembly (Working and counter electrodes: Pt wire, reference electrode: Pt wire) and calibrated using FeCp2/FeCp2+ as internal standard. The HOMO data was corrected using ferrocene as internal standard against a saturated calomel electrode (SCE).

Density functional theory calculation



[0182] Molecular structures are optimized employing the BP86 functional and the resolution of identity approach (RI). Excitation energies are calculated using the (BP86) optimized structures employing Time-Dependent DFT (TD-DFT) methods. Orbital and excited state energies are calculated with the B3LYP functional. Def2-SVP basis sets (and a m4-grid for numerical integration are used. The Turbomole program package is used for all calculations.

Photophysical measurements



[0183] 

Sample pretreatment: Spin-coating

Apparatus: Spin150, SPS euro.



[0184] The sample concentration is 10 mg/ml, dissolved in a suitable solvent.
Program: 1) 3 s at 400 U/min; 20 s at 1000 U/min at 1000 Upm/s. 3) 10 s at 4000 U/min at 1000 Upm/s. After coating, the films are tried at 70 °C for 1 min.

[0185] Photoluminescence spectroscopy and Time-Correlated Single-Photon Counting (TCSPC) Steady-state emission spectroscopy is measured by a Horiba Scientific, Modell FluoroMax-4 equipped with a 150 W Xenon-Arc lamp, excitation- and emissions monochromators and a Hamamatsu R928 photomultiplier and a time-correlated single-photon counting option. Emissions and excitation spectra are corrected using standard correction fits.

[0186] Excited state lifetimes are determined employing the same system using the TCSPC method with FM-2013 equipment and a Horiba Y von TCSPC hub.

Excitation sources:

NanoLED 370 (wavelength: 371 nm, puls duration: 1,1 ns)

NanoLED 290 (wavelength: 294 nm, puls duration: <1 ns)

SpectraLED 310 (wavelength: 314 nm)

SpectraLED 355 (wavelength: 355 nm).



[0187] Data analysis (exponential fit) is done using the software suite DataStation and DAS6 analysis software. The fit is specified using the chi-squared-test.

Photoluminescence quantum yield measurements



[0188] For photoluminescence quantum yield (PLQY) measurements an Absolute PL Quantum Yield Measurement C9920-03G system (Hamamatsu Photonics) is used. Quantum yields and CIE coordinates are determined using the software U6039-05 version 3.6.0.

[0189] Emission maxima are given in nm, quantum yields Φ in % and CIE coordinates as x,y values. PLQY is determined using the following protocol:
  1. 1) Quality assurance: Anthracene in ethanol (known concentration) is used as reference
  2. 2) Excitation wavelength: the absorption maximum of the organic molecule is determined and the molecule is excited using this wavelength
  3. 3) Measurement
Quantum yields are measured for sample of solutions or films under nitrogen atmosphere. The yield is calculated using the equation:

wherein nphoton denotes the photon count and Int. the intensity.

Production and Characterization of Optoelectronic Devices



[0190] Optoelectronic devices, e.g. OLED devices, comprising organic molecules according to the invention can be produced via vacuum-deposition methods. If a layer contains more than one compound, the weight-percentage of one or more compounds is given in %. The total weight-percentage values amount to 100 %, thus if a value is not given, the fraction of this compound equals to the difference between the given values and 100 %.

[0191] The not fully optimized OLEDs are characterized using standard methods and measuring electroluminescence spectra, the external quantum efficiency (in %) in dependency on the intensity, calculated using the light detected by the photodiode, and the current. The OLED device lifetime is extracted from the change of the luminance during operation at constant current density. The LT50 value corresponds to the time, where the measured luminance decreased to 50 % of the initial luminance, analogously LT80 corresponds to the time point, at which the measured luminance decreased to 80 % of the initial luminance, LT 95 to the time point, at which the measured luminance decreased to 95 % of the initial luminance etc.

[0192] Accelerated lifetime measurements are performed (e.g. applying increased current densities). Exemplarily LT80 values at 500 cd/m2 are determined using the following equation:

wherein L0 denotes the initial luminance at the applied current density.

[0193] The values correspond to the average of several pixels (typically two to eight), the standard deviation between these pixels is given.

HPLC-MS



[0194] HPLC-MS spectroscopy is performed on a HPLC by Agilent (1100 series) with MS-detector (Thermo LTQ XL).

[0195] Exemplary a typical HPLIC method is as follows: a reverse phase column 4,6mm x 150mm, particle size 3,5 µm from Agilent (ZORBAX Eclipse Plus 95Å C18, 4.6 x 150 mm, 3.5 µm HPLC column) is used in the HPLC. The HPLC-MS measurements are performed at room temperature (rt) with the following gradients
Flow rate [ml/min]time [min]A[%]B[%]C[%]
2.5 0 40 50 10
2.5 5 40 50 10
2.5 25 10 20 70
2.5 35 10 20 70
using the following solvent mixtures:
solvent A: H2O (90%) MeCN (10%)
solvent B: H2O (10%) MeCN (90%)
solvent C: THF (50%) MeCN (50%)


[0196] An injection volume of 5 µL from a solution with a concentration of 0.5 mg/mL of the analyte is taken for the measurements.

[0197] Ionisation of the probe is performed using an APCI (atmospheric pressure chemical ionization) source either in positive (APCI +) or negative (APCI -) ionization mode.

Example 1



[0198] 



[0199] Example 1 was synthesized according to

AAV1-1 (yield of 82%), wherein 3-chloro-4-fluorophenylboronic acid (CAS 144432-85-9) was used as reactant E0-0 and 4-chloro-3-fluoropyridine (CAS 2546-56-7) was used as reactant E0-1,

AAV1-2 (yield of 39%), wherein bis(pinacolato)diboron (CAS 73183-34-3) was used as reactant,

AAV1-3 (yield of 39%), wherein 4,6-dichloro-2-phenyl-pyrimidine (CAS 3740-92-9) was used as reactant E0-1

AAV3 (yield of 36%).
HPLC-MS (APCI -): m/z = 1170.37; calculated: m/z = 1171.37.



[0200] Figure 1 depicts the emission spectrum of example 1 (10 % by weight in PMMA). The emission maximum (λmax) is at 468 nm. The photoluminescence quantum yield (PLQY) is 68%, the full width at half maximum (FWHM) is 0.44 eV and the emission lifetime is 71 µs. The resulting CIEx coordinate is determined as 0.17 and the CIEy coordinate as 0.21.

Additional Examples of Organic Molecules of the Invention



[0201] 
















































































































































































































































































































































Figure 1



[0202] The drawing of the figure 1 shows:
Emission spectrum of example 1 (10% by weight) in PMMA.


Claims

1. Organic molecule, comprising

- two identical first chemical moieties comprising a structure of formula I,

- four second chemical moieties, each independently from another comprising a structure of formula II,

and

- one third chemical moiety RA, comprising a structure of formula Py,

wherein each first chemical moiety is linked to two of the four second chemical moieties via a single bond;

wherein the two first chemical moieties are linked to each other via the third chemical moiety RA, wherein each dotted bond in formula Py indicates the binding site of the third chemical moiety RA to one of the two first chemical moieties;

wherein

T is selected from the group consisting of the third chemical moiety RA and R1;

V is selected from the group consisting of RA and R1;

W is the binding site of a single bond linking one of the first chemical moieties to one of the four second chemical moieties or is selected from the group consisting of RA and R1;

X is the binding site of a single bond linking one of the first chemical moieties to one of the four second chemical moieties or is selected from the group consisting of RA and R1;

Y is the binding site of a single bond linking one of the first chemical moiety to one of the four second chemical moieties or is selected from the group consisting of RA and R1;

Q is selected from the group consisting of N and C-RPy;

LT is selected from the group consisting of N and C-RI;

LV is selected from the group consisting of N and C-RI;

LW is selected from the group consisting of N and C-RW;

RW is the binding site of a single bond linking one of the first chemical moieties to one of the four second chemical moieties or is RI;

RX is the binding site of a single bond linking one of the first chemical moieties to one of the four second chemical moieties or is RI;

RY is the binding site of a single bond linking one of the first chemical moieties to one of the four second chemical moieties or is RI;

# represents the binding site of a single bond linking the second chemical moieties to one of the first chemical moieties;

Z is at each occurrence independently from another selected from the group consisting of: a direct bond, CR3R4, C=CR3R4, C=O, C=NR3, NR3, O, SiR3R4, S, S(O) and S(O)2;

R1 is at each occurrence independently from another selected from the group consisting of: hydrogen, deuterium,

C1-C5-alkyl,
wherein one or more hydrogen atoms are optionally substituted by deuterium;

C2-C8-alkenyl,
wherein one or more hydrogen atoms are optionally substituted by deuterium;

C2-C8-alkynyl,
wherein one or more hydrogen atoms are optionally substituted by deuterium; and

C6-C18-aryl,
which is optionally substituted with one or more substituents R6;

RI is at each occurrence independently from another selected from the group consisting of: hydrogen, deuterium,

C1-C5-alkyl,
wherein one or more hydrogen atoms are optionally substituted by deuterium;

C2-C8-alkenyl,
wherein one or more hydrogen atoms are optionally substituted by deuterium;

C2-C8-alkynyl,
wherein one or more hydrogen atoms are optionally substituted by deuterium; and

C6-C18-aryl,
which is optionally substituted with one or more substituents R6;

RTz is at each occurrence independently from another selected from the group consisting of hydrogen,
deuterium,
C1-C5-alkyl,
wherein one or more hydrogen atoms are optionally substituted by deuterium;
C6-C18-aryl,
which is optionally substituted with one or more substituents R6; and C3-C17-heteroaryl,
which is optionally substituted with one or more substituents R6;

RPy is at each occurrence independently from another selected from the group consisting of hydrogen,
deuterium,
C1-C5-alkyl,
wherein one or more hydrogen atoms are optionally substituted by deuterium;
C6-C18-aryl,
which is optionally substituted with one or more substituents R6; and C3-C17-heteroaryl,
which is optionally substituted with one or more substituents R6;

Ra, R3 and R4 is at each occurrence independently from another selected from the group consisting of: hydrogen, deuterium, N(R5)2, OR5, Si(R5)3, B(OR5)2, OSO2R5, CF3, CN, F, Br, I, C1-C40-alkyl,

which is optionally substituted with one or more substituents R5 and

wherein one or more non-adjacent CH2-groups are optionally substituted by R5C=CR5, C≡C, Si(R5)2, Ge(R5)2, Sn(R5)2, C=O, C=S, C=Se, C=NR5, P(=O)(R5), SO, SO2, NR5, O, S or CONR5;

C1-C40-alkoxy,

which is optionally substituted with one or more substituents R5 and

wherein one or more non-adjacent CH2-groups are optionally substituted by R5C=CR5, C≡C, Si(R5)2, Ge(R5)2, Sn(R5)2, C=O, C=S, C=Se, C=NR5, P(=O)(R5), SO, SO2, NR5, O, S or CONR5;

C1-C40-thioalkoxy,

which is optionally substituted with one or more substituents R5 and

wherein one or more non-adjacent CH2-groups are optionally substituted by R5C=CR5, C≡C, Si(R5)2, Ge(R5)2, Sn(R5)2, C=O, C=S, C=Se, C=NR5, P(=O)(R5), SO, SO2, NR5, O, S or CONR5;

C2-C40-alkenyl,

which is optionally substituted with one or more substituents R5 and

wherein one or more non-adjacent CH2-groups are optionally substituted by R5C=CR5, C≡C, Si(R5)2, Ge(R5)2, Sn(R5)2, C=O, C=S, C=Se, C=NR5, P(=O)(R5), SO, SO2, NR5, O, S or CONR5;

C2-C40-alkynyl,

which is optionally substituted with one or more substituents R5 and

wherein one or more non-adjacent CH2-groups are optionally substituted by R5C=CR5, C≡C, Si(R5)2, Ge(R5)2, Sn(R5)2, C=O, C=S, C=Se, C=NR5, P(=O)(R5), SO, SO2, NR5, O, S or CONR5;

C6-C60-aryl,
which is optionally substituted with one or more substituents R5;
C3-C57-heteroaryl,
which is optionally substituted with one or more substituents R5; and

a mono- or polycyclic, aliphatic, aromatic and/or benzo-fused ring system formed by ring-closure with one or more of the other substituents selected from the group consisting of Ra, R3, R4 and R5;

R5 is at each occurrence independently from another selected from the group consisting of hydrogen, deuterium, N(R6)2, OR6, Si(R6)3, B(OR6)2, OSO2R6, CF3, CN, F, Br, I, C1-C40-alkyl,

which is optionally substituted with one or more substituents R6 and

wherein one or more non-adjacent CH2-groups are optionally substituted by R6C=CR6, C≡C, Si(R6)2, Ge(R6)2, Sn(R6)2, C=O, C=S, C=Se, C=NR6, P(=O)(R6), SO, SO2, NR6, O, S or CONR6;

C1-C40-alkoxy,

which is optionally substituted with one or more substituents R6 and

wherein one or more non-adjacent CH2-groups are optionally substituted by R6C=CR6, C≡C, Si(R6)2, Ge(R6)2, Sn(R6)2, C=O, C=S, C=Se, C=NR6, P(=O)(R6), SO, SO2, NR6, O, S or CONR6;

C1-C40-thioalkoxy,

which is optionally substituted with one or more substituents R6 and

wherein one or more non-adjacent CH2-groups are optionally substituted by R6C=CR6, C≡C, Si(R6)2, Ge(R6)2, Sn(R6)2, C=O, C=S, C=Se, C=NR6, P(=O)(R6), SO, SO2, NR6, O, S or CONR6;

C2-C40-alkenyl,

which is optionally substituted with one or more substituents R6 and

wherein one or more non-adjacent CH2-groups are optionally substituted by R6C=CR6, C≡C, Si(R6)2, Ge(R6)2, Sn(R6)2, C=O, C=S, C=Se, C=NR6, P(=O)(R6), SO, SO2, NR6, O, S or CONR6;

C2-C40-alkynyl,

which is optionally substituted with one or more substituents R6 and

wherein one or more non-adjacent CH2-groups are optionally substituted by R6C=CR6, C≡C, Si(R6)2, Ge(R6)2, Sn(R6)2, C=O, C=S, C=Se, C=NR6, P(=O)(R6), SO, SO2, NR6, O, S or CONR6;

C6-C60-aryl,
which is optionally substituted with one or more substituents R6; and
C3-C57-heteroaryl,
which is optionally substituted with one or more substituents R6; and

a mono- or polycyclic, aliphatic, aromatic and/or benzo-fused ring system formed by ring-closure with one or more of the other substituents selected from the group consisting of Ra, R3, R4 and R5;

R6 is at each occurrence independently from another selected from the group consisting of:

hydrogen, deuterium, OPh, CF3, CN, F,

C1-C5-alkyl,
wherein one or more hydrogen atoms are optionally, independently from each other substituted by deuterium, CN, CF3, or F;

C1-C5-alkoxy,
wherein one or more hydrogen atoms are optionally, independently from each other substituted by deuterium, CN, CF3, or F;

C1-C5-thioalkoxy,
wherein one or more hydrogen atoms are optionally, independently from each other substituted by deuterium, CN, CF3, or F;

C2-C5-alkenyl,
wherein one or more hydrogen atoms are optionally, independently from each other substituted by deuterium, CN, CF3, or F;

C2-C5-alkynyl,
wherein one or more hydrogen atoms are optionally, independently from each other substituted by deuterium, CN, CF3, or F;

C6-C18-aryl,
which is optionally substituted with one or more C1-C5-alkyl substituents;

C3-C17-heteroaryl,
which is optionally substituted with one or more C1-C5-alkyl substituents;

N(C6-C18-aryl)2;

N(C3-C17-heteroaryl)2,

and N(C3-C17-heteroaryl)(C6-C18-aryl);

wherein, optionally, the substituents Ra, R3, R4 or R5 independently from each other form a mono- or polycyclic, aliphatic, aromatic and/or benzo-fused ring system with one or more substituents of the other substituents Ra, R3, R4 or R5;

wherein the terms alkyl, alkenyl and alkynyl can refer to linear, branched, and cyclic substituents;

wherein the mono- or polycyclic, aliphatic, aromatic and/or benzo-fused ring system is optionally substituted with at least one substituent R5, and
optionally forms a mono- or polycyclic, aliphatic, aromatic and/or benzo-fused ring system together with one or more of the other Ra, R3, R4 or R5 within the organic molecule;

wherein the mono- or polycyclic, aliphatic, aromatic and/or benzo-fused ring system is optionally substituted with at least one substituent R6;

wherein
at least one Q is N;
exactly one substituent selected from the group consisting of T, V, W, X and Y is RA;
exactly one ring member selected from the group consisting of LT, LV, and LW is N;

exactly one substituent selected from the group consisting of W, Y and X represents the binding site of a single bond linking one of the first chemical moieties to one of the four second chemical moieties; and

exactly one substituent selected from the group consisting of RW, RY and RX represents the binding site of a single bond linking one of the first chemical moieties to one of the four second chemical moieties.


 
2. Organic molecule according to claim 1, wherein the two first identical chemical moieties comprise a structure of formula laa:

wherein

W# is the binding site of a single bond linking one of the first chemical moieties to one of the second chemical moieties or is R1,

Y# is the binding site of a single bond linking one of the first chemical moieties to one of the second chemical moieties or is R1,

LW# is selected from the group consisting of N and C-R1,

RD is the binding site of a single bond linking one of the first chemical moieties to one of the second chemical moieties;

wherein exactly one substituent selected from the group consisting of W# and Y# is the binding site of a single bond linking one of the first chemical moieties to one of the four second chemical moieties; and

wherein exactly one ring member selected from the group consisting of LV, LT, LW# is N.


 
3. Organic molecule according to claim 1 or 2, wherein R1 and RI is at each occurrence independently from each other selected from the group consisting of: H, methyl, mesityl, tolyl, and phenyl.
 
4. Organic molecule according to one or more of claims 1 to 3, wherein RTz and RPy is independently from each other selected from the group consisting of: H, methyl, and phenyl.
 
5. Organic molecule according to one or more of claims 1 to 4, wherein the four second chemical moieties, each at each occurrence independently from another comprise a structure of formula IIa:


 
6. Organic molecule according to one or more of claims 1 to 5, wherein the four second chemical moieties, at each occurrence independently from another comprise a structure of formula IIb:

wherein

Rb is at each occurrence independently from another selected from the group consisting of:

deuterium, N(R5)2, OR5, Si(R5)3, B(OR5)2, OSO2R5, CF3, CN, F, Br, I,

C1-C40-alkyl,

which is optionally substituted with one or more substituents R5 and

wherein one or more non-adjacent CH2-groups are optionally substituted by R5C=CR5, C≡C, Si(R5)2, Ge(R5)2, Sn(R5)2, C=O, C=S, C=Se, C=NR5, P(=O)(R5), SO, SO2, NR5, O, S or CONR5;

C1-C40-alkoxy,

which is optionally substituted with one or more substituents R5 and

wherein one or more non-adjacent CH2-groups are optionally substituted by R5C=CR5, C≡C, Si(R5)2, Ge(R5)2, Sn(R5)2, C=O, C=S, C=Se, C=NR5, P(=O)(R5), SO, SO2, NR5, O, S or CONR5;

C1-C40-thioalkoxy,

which is optionally substituted with one or more substituents R5 and

wherein one or more non-adjacent CH2-groups are optionally substituted by R5C=CR5, C≡C, Si(R5)2, Ge(R5)2, Sn(R5)2, C=O, C=S, C=Se, C=NR5, P(=O)(R5), SO, SO2, NR5, O, S or CONR5;

C2-C40-alkenyl,

which is optionally substituted with one or more substituents R5 and

wherein one or more non-adjacent CH2-groups are optionally substituted by R5C=CR5, C≡C, Si(R5)2, Ge(R5)2, Sn(R5)2, C=O, C=S, C=Se, C=NR5, P(=O)(R5), SO, SO2, NR5, O, S or CONR5;

C2-C40-alkynyl,

which is optionally substituted with one or more substituents R5 and

wherein one or more non-adjacent CH2-groups are optionally substituted by R5C=CR5, C≡C, Si(R5)2, Ge(R5)2, Sn(R5)2, C=O, C=S, C=Se, C=NR5, P(=O)(R5), SO, SO2, NR5, O, S or CONR5;

C6-C60-aryl,
which is optionally substituted with one or more substituents R5; and

C3-C57-heteroaryl,
which is optionally substituted with one or more substituents R5.


 
7. Organic molecule according to one or more of claims 1 to 5, wherein the four second chemical moieties, each at each occurrence independently from another comprise a structure of formula IIc:

wherein

Rb is at each occurrence independently from another selected from the group consisting of deuterium, N(R5)2, OR5, Si(R5)3, B(OR5)2, OSO2R5, CF3, CN, F, Br, I,

C1-C40-alkyl,

which is optionally substituted with one or more substituents R5 and

wherein one or more non-adjacent CH2-groups are optionally substituted by R5C=CR5, C≡C, Si(R5)2, Ge(R5)2, Sn(R5)2, C=O, C=S, C=Se, C=NR5, P(=O)(R5), SO, SO2, NR5, O, S or CONR5;

C1-C40-alkoxy,

which is optionally substituted with one or more substituents R5 and

wherein one or more non-adjacent CH2-groups are optionally substituted by R5C=CR5, C≡C, Si(R5)2, Ge(R5)2, Sn(R5)2, C=O, C=S, C=Se, C=NR5, P(=O)(R5), SO, SO2, NR5, O, S or CONR5;

C1-C40-thioalkoxy,

which is optionally substituted with one or more substituents R5 and

wherein one or more non-adjacent CH2-groups are optionally substituted by R5C=CR5, C≡C, Si(R5)2, Ge(R5)2, Sn(R5)2, C=O, C=S, C=Se, C=NR5, P(=O)(R5), SO, SO2, NR5, O, S or CONR5;

C2-C40-alkenyl,

which is optionally substituted with one or more substituents R5 and

wherein one or more non-adjacent CH2-groups are optionally substituted by R5C=CR5, C≡C, Si(R5)2, Ge(R5)2, Sn(R5)2, C=O, C=S, C=Se, C=NR5, P(=O)(R5), SO, SO2, NR5, O, S or CONR5;

C2-C40-alkynyl,

which is optionally substituted with one or more substituents R5 and

wherein one or more non-adjacent CH2-groups are optionally substituted by R5C=CR5, C≡C, Si(R5)2, Ge(R5)2, Sn(R5)2, C=O, C=S, C=Se, C=NR5, P(=O)(R5), SO, SO2, NR5, O, S or CONR5;

C6-C60-aryl,
which is optionally substituted with one or more substituents R5; and

C3-C57-heteroaryl,
which is optionally substituted with one or more substituents R5.


 
8. Organic molecule according to claim 6 or 7, wherein Rb is at each occurrence independently from another selected from the group consisting of:

- Me, iPr, tBu, CN, CF3,

- Ph, which is optionally substituted with one or more substituents independently from each other selected from the group consisting of Me, iPr, tBu, CN, CF3 and Ph;

- pyridinyl, which is optionally substituted with one or more substituents independently from each other selected from the group consisting of Me, iPr, tBu, CN, CF3 and Ph;

- pyrimidyl, which is optionally substituted with one or more substituents independently from each other selected from the group consisting of Me, iPr, tBu, CN, CF3 and Ph;

- carbazolyl, which is optionally substituted with one or more substituents independently from each other selected from the group consisting of Me, iPr, tBu, CN, CF3 and Ph;

- triazinyl, which is optionally substituted with one or more substituents independently from each other selected from the group consisting of Me, iPr, tBu, CN, CF3, and Ph;
and

- N(Ph)2.


 
9. Method for preparing an organic molecule according to claims 1 to 8, comprising providing a chloro-fluoro-tri-R1-substituted phenylboronic acid as a reactant.
 
10. Use of an organic molecule according to one or more of claims 1 to 8 as a luminescent emitter and/or as a host material and/or as an electron transport material and/or as a hole injection material and/or as a hole blocking material in an optoelectronic device.
 
11. Use according to claim 10, wherein the optoelectronic device is selected from the group consisting of:

• organic light-emitting diodes (OLEDs),

• light-emitting electrochemical cells,

• OLED-sensors,

• organic diodes,

• organic solar cells,

• organic transistors,

• organic field-effect transistors,

• organic lasers, and

• down-conversion elements.


 
12. Composition, comprising:

(a) an organic molecule according to one or more of claims 1 to 8, in particular in the form of an emitter and/or a host, and

(b) an emitter and/or host material, which differs from the organic molecule in structure, and

(c) optionally, a dye and/or a solvent.


 
13. Optoelectronic device, comprising an organic molecule according to one or more of claims 1 to 8 or a composition according to claim 12, in particular in form of a device selected from the group consisting of: organic light-emitting diode (OLED), light-emitting electrochemical cell, OLED-sensor, organic diode, organic solar cell, organic transistor, organic field-effect transistor, organic laser, and down-conversion element.
 
14. Optoelectronic device according to claim 13, comprising or consisting of:

- a substrate,

- an anode, and

- a cathode, wherein the anode or the cathode are disposed on the substrate, and

- a light-emitting layer, which is arranged between the anode and the cathode and which comprises the organic molecule or the composition.


 
15. Method for producing an optoelectronic device, wherein an organic molecule according to any one of claims 1 to 8 or a composition according to claim 12 is used, in particular comprising processing of the organic molecule or composition by a vacuum evaporation method or from a solution.
 




Drawing







Search report









Search report




Cited references

REFERENCES CITED IN THE DESCRIPTION



This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Non-patent literature cited in the description